<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK3794" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK3794/" /><meta name="ncbi_pagename" content="Creatine Deficiency Syndromes - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Creatine Deficiency Syndromes - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Creatine Deficiency Syndromes" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/12/10" /><meta name="citation_author" content="Saadet Mercimek-Mahmutoglu" /><meta name="citation_author" content="Gajja S Salomons" /><meta name="citation_pmid" content="20301745" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK3794/" /><meta name="citation_keywords" content="Cerebral Creatine Deficiency Syndromes" /><meta name="citation_keywords" content="Cerebral Creatine Deficiency Syndromes" /><meta name="citation_keywords" content="Guanidinoacetate Methyltransferase (GAMT) Deficiency" /><meta name="citation_keywords" content="Creatine Transporter (CRTR) Deficiency" /><meta name="citation_keywords" content="L-Arginine:Glycine Amidinotransferase (AGAT) Deficiency" /><meta name="citation_keywords" content="Glycine amidinotransferase, mitochondrial" /><meta name="citation_keywords" content="Guanidinoacetate N-methyltransferase" /><meta name="citation_keywords" content="Sodium- and chloride-dependent creatine transporter 1" /><meta name="citation_keywords" content="GAMT" /><meta name="citation_keywords" content="GATM" /><meta name="citation_keywords" content="SLC6A8" /><meta name="citation_keywords" content="Creatine Deficiency Syndromes" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Creatine Deficiency Syndromes" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Saadet Mercimek-Mahmutoglu" /><meta name="DC.Contributor" content="Gajja S Salomons" /><meta name="DC.Date" content="2015/12/10" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK3794/" /><meta name="description" content="The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The phenotype of CRTR deficiency in affected males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females heterozygous for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype." /><meta name="og:title" content="Creatine Deficiency Syndromes" /><meta name="og:type" content="book" /><meta name="og:description" content="The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The phenotype of CRTR deficiency in affected males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females heterozygous for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK3794/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/creatine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK3794/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88AABEE0424CA10000000002ED0123.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK3794_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK3794_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cranio-md/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cf/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK3794_"><span class="title" itemprop="name">Creatine Deficiency Syndromes</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Cerebral Creatine Deficiency Syndromes</div><p class="contrib-group"><span itemprop="author">Saadet Mercimek-Mahmutoglu</span>, MD, PhD, FCCMG and <span itemprop="author">Gajja S Salomons</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK3794_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK3794_ai__"><div class="contrib half_rhythm"><span itemprop="author">Saadet Mercimek-Mahmutoglu</span>, MD, PhD, FCCMG<div class="affiliation small">Assistant Professor, Division of Clinical and Metabolic Genetics<br />Department of Pediatrics<br />University of Toronto<br />The Hospital for Sick Children<br />Toronto, Ontario, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.sdikkcis@swerdna.tedaas" class="oemail">ac.sdikkcis@swerdna.tedaas</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Gajja S Salomons</span>, PhD<div class="affiliation small">Professor, Department of Clinical Chemistry<br />Metabolic Unit<br />VU University Medical Center<br />Amsterdam, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmuv@snomolas.g" class="oemail">ln.cmuv@snomolas.g</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 15, 2009</span>; Last Update: <span itemprop="dateModified">December 10, 2015</span>.</p><p><em>Estimated reading time: 36 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="creatine.Summary" itemprop="description"><h2 id="_creatine_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of CRTR deficiency in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Cerebral creatine deficiency in brain MR spectroscopy (<sup>1</sup>H-MRS) is the characteristic hallmark of all CCDS. Diagnosis of CCDS relies on: measurement of guanidinoacetate (GAA), creatine, and creatinine in urine and plasma; and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the three genes involved, <i>GAMT</i>, <i>GATM</i>, and <i>SLC6A8</i>. If molecular genetic test results are inconclusive, GAMT enzyme activity (in cultured fibroblast or lymphoblasts), GATM enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> GAMT deficiency and AGAT deficiency are treated with oral creatine monohydrate to replenish cerebral creatine levels. Treatment of GAMT deficiency requires supplementation of ornithine and dietary restriction of arginine or protein. In males with CRTR deficiency creatine supplementation alone does not improve clinical outcome and does not result in replenished cerebral creatine levels; likewise, high-dose L-arginine and L-glycine supplementation so far has not consistently improve clinical or biochemical outcome in males although some have been reported to have increased muscle mass and improved motor and personal social IQ skills. One female with intractable epilepsy responded to high-dose L-arginine and L-glycine supplementation with cessation of seizures.</p><p><i>Prevention of primary manifestations</i>: Early treatment at the asymptomatic stage of the disease in individuals with GAMT and AGAT deficiencies appears to be beneficial: treatment in newborn sibs of individuals with AGAT or GAMT deficiency prevented disease manifestations.</p><p><i>Surveillance</i>: In those treated with creatine monohydrate, routine measurement of renal function to detect possible creatine-associated nephropathy is warranted.</p><p><i>Evaluation of relatives at risk:</i> Early diagnosis of neonates at risk for GAMT deficiency, AGAT deficiency, and CRTR deficiency by biochemical or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> allows for early diagnosis and treatment of the defects in creatine metabolism.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>GAMT deficiency and AGAT deficiency are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an individual with GAMT deficiency or AGAT deficiency has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. CRTR deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Mothers who are carriers have a 50% chance of transmitting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy; sons who inherit the pathogenic variant will be affected; daughters who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and may have learning and behavior problems. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible for all three defects in creatine metabolism if the pathogenic variants in the family are known.</p></div></div><div id="creatine.GeneReview_Scope"><h2 id="_creatine_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="creatine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_creatine.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Creatine Deficiency Syndromes: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_creatine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Guanidinoacetate methyltransferase (GAMT) deficiency</div></li><li class="half_rhythm"><div>L-arginine:glycine amidinotransferase (AGAT) deficiency</div></li><li class="half_rhythm"><div>Creatine transporter (CRTR) deficiency</div></li></ul>
</td></tr></tbody></table></div></div></div><div id="creatine.Diagnosis"><h2 id="_creatine_Diagnosis_">Diagnosis</h2><p>The cerebral creatine deficiency syndromes (CCDS) are inborn errors of creatine metabolism that include [<a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</a>]:</p><ul><li class="half_rhythm"><div>Two creatine biosynthesis defects (both inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner):</div><ul><li class="half_rhythm"><div>Guanidinoacetate methyltransferase (GAMT) deficiency</div></li><li class="half_rhythm"><div>L-arginine:glycine amidinotransferase (AGAT) deficiency</div></li></ul></li><li class="half_rhythm"><div>One creatine transporter defect (inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner): creatine transporter (CRTR) deficiency</div></li></ul><div id="creatine.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Cerebral creatine deficiency syndromes (CCDS) <b>should be suspected</b> in:</p><ul><li class="half_rhythm"><div>A young child with developmental delay, hypotonia, seizures, and movement disorder;</div></li><li class="half_rhythm"><div>An older child with intellectual disability, epilepsy, movement disorder, and behavior problems.</div></li></ul><p>See <a class="figpopup" href="/books/NBK3794/table/creatine.T.clinical_features_of_gamt_aga/?report=objectonly" target="object" rid-figpopup="figcreatineTclinicalfeaturesofgamtaga" rid-ob="figobcreatineTclinicalfeaturesofgamtaga">Table 1</a>.</p><div id="creatine.T.clinical_features_of_gamt_aga" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Clinical Features of GAMT, AGAT, and CRTR Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.clinical_features_of_gamt_aga/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.clinical_features_of_gamt_aga_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" style="text-align:left;vertical-align:middle;">Deficiency</th><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" style="text-align:left;vertical-align:middle;"># of Affected Persons</th><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" style="text-align:left;vertical-align:middle;">ID</th><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Epilepsy</th><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Movement Disorder&#x000a0;<sup>1</sup></th><th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" style="text-align:left;vertical-align:middle;">Behavior Problems</th></tr><tr><th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Frequency</th><th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Drug Resistance</th><th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th><th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severity</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>GAMT</b></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">110</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to severe</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">69/80 (86%)&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">46%&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30/80 (37.5%)&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to severe&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperactivity, autism spectrum disorder, aggressive behavior, self-injurious behavior</td></tr><tr><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>AGAT</b></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to moderate</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/14 (14%)</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td></tr><tr><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>CRTR</b></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;160&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to severe</td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">59/101 (60%) males&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/59 (5%)&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41/101 (40%)&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to severe&#x000a0;<sup>4</sup></td><td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">86/101 (85%) attention deficit hyperactivity, autism spectrum disorder&#x000a0;<sup>3</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ID = intellectual disability</p></div></dd><dt>1. </dt><dd><div id="creatine.TF.1.1"><p class="no_margin">Dystonia, chorea, choreoathetosis, ataxia</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.1.2"><p class="no_margin">Based on the 80 patients reported by <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al [2014]</a>, and <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al [2014a]</a></p></div></dd><dt>3. </dt><dd><div id="creatine.TF.1.3"><p class="no_margin">The authors are aware of more than 160 patients; however, the clinical characteristics have only been described for ~101 males from 85 families. The most recent international registry paper to review these data is <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</a>.</p></div></dd><dt>4. </dt><dd><div id="creatine.TF.1.4"><p class="no_margin">101 males reported by <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al [2013b]</a> had movement disorder including ataxia (29%) and dystonia or athetosis (11%).</p></div></dd></dl></div></div></div><div id="creatine.Screening_Tests"><h4>Screening Tests</h4><p><b>Levels of guanidinoacetate (GAA), creatine, and creatinine</b> are measured in urine (<a class="figpopup" href="/books/NBK3794/table/creatine.T.urinary_metabolites_by_ccds_d/?report=objectonly" target="object" rid-figpopup="figcreatineTurinarymetabolitesbyccdsd" rid-ob="figobcreatineTurinarymetabolitesbyccdsd">Table 2</a>), plasma (<a class="figpopup" href="/books/NBK3794/table/creatine.T.plasma_concentration_of_metab/?report=objectonly" target="object" rid-figpopup="figcreatineTplasmaconcentrationofmetab" rid-ob="figobcreatineTplasmaconcentrationofmetab">Table 3</a>), and cerebrospinal fluid (CSF) (<a class="figpopup" href="/books/NBK3794/table/creatine.T.csf_concentration_of_metaboli/?report=objectonly" target="object" rid-figpopup="figcreatineTcsfconcentrationofmetaboli" rid-ob="figobcreatineTcsfconcentrationofmetaboli">Table 4</a>) [<a class="bk_pop" href="#creatine.REF.almeida.2004.214">Almeida et al 2004</a>, <a class="bk_pop" href="#creatine.REF.cognat.2004.1459">Cognat et al 2004</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</a>, <a class="bk_pop" href="#creatine.REF.m_rkrid.2015.760">M&#x000f8;rkrid et al 2015</a>].</p><div id="creatine.T.urinary_metabolites_by_ccds_d" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Urinary Metabolites by CCDS Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.urinary_metabolites_by_ccds_d/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.urinary_metabolites_by_ccds_d_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Deficiency</th><th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">GAA&#x000a0;<sup>1</sup> Concentration</th><th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatine Concentration</th><th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatine/Creatinine Ratio</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>GAMT</b></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low to low normal&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low normal</td></tr><tr><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>AGAT</b></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low to low normal&#x000a0;<sup>4</sup></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low normal&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low normal</td></tr><tr><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>CRTR</b></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal&#x000a0;<sup>5</sup></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Females</b></td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to mildly elevated</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="creatine.TF.2.1"><p class="no_margin">Guanidinoacetate</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.2.2"><p class="no_margin">Pathognomonic finding</p></div></dd><dt>3. </dt><dd><div id="creatine.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al [2002]</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al [2012]</a></p></div></dd><dt>4. </dt><dd><div id="creatine.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.almeida.2004.214">Almeida et al [2004]</a>, <a class="bk_pop" href="#creatine.REF.cognat.2004.1459">Cognat et al [2004]</a></p></div></dd><dt>5. </dt><dd><div id="creatine.TF.2.5"><p class="no_margin">If GAA is presented as guanidinoacetate mmol/mol creatinine, the values may appear slightly increased because of the generally lower creatinine values in males with CRTR deficiency.</p></div></dd><dt>6. </dt><dd><div id="creatine.TF.2.6"><p class="no_margin">Diagnostic finding [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</a>]</p></div></dd></dl></div></div></div><div id="creatine.T.plasma_concentration_of_metab" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Plasma Concentration of Metabolites by CCDS Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.plasma_concentration_of_metab/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.plasma_concentration_of_metab_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Deficiency</th><th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">GAA&#x000a0;<sup>1</sup></th><th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatine</th><th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatinine</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>GAMT</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Low to normal&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>AGAT</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low to low normal&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>CRTR</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Females</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Normal</b></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See age-related reference range&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="creatine.TF.3.1"><p class="no_margin">Guanidinoacetate</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</a></p></div></dd><dt>3. </dt><dd><div id="creatine.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.almeida.2004.214">Almeida et al [2004]</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2015.141">van de Kamp et al [2015]</a></p></div></dd><dt>4. </dt><dd><div id="creatine.TF.3.4"><p class="no_margin">Determination of plasma creatinine concentration alone cannot identify a CCDS.</p></div></dd></dl></div></div></div><div id="creatine.T.csf_concentration_of_metaboli" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>CSF Concentration of Metabolites by CCDS Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.csf_concentration_of_metaboli/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.csf_concentration_of_metaboli_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Deficiency</th><th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">GAA&#x000a0;<sup>1</sup></th><th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatine</th><th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Creatinine</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>GAMT</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated&#x000a0;<sup>2</sup></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td></tr><tr><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>AGAT</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td></tr><tr><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>CRTR</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to mildly elevated&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to mildly elevated&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td></tr><tr><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Females</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No data</td></tr><tr><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Normal</b></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See age-related reference range&#x000a0;<sup>4</sup></td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="creatine.TF.4.1"><p class="no_margin">Guanidinoacetate</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</a></p></div></dd><dt>3. </dt><dd><div id="creatine.TF.4.3"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al [2013b]</a></p></div></dd><dt>4. </dt><dd><div id="creatine.TF.4.4"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.almeida.2004.214">Almeida et al [2004]</a>, <a class="bk_pop" href="#creatine.REF.cognat.2004.1459">Cognat et al [2004]</a></p></div></dd></dl></div></div></div><p><b>Brain imaging for in vivo assessment of brain creatine levels.</b> Proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) reveals almost complete depletion of the cerebral creatine pool in all individuals with GAMT deficiency and AGAT deficiency and in males with CRTR deficiency. Partial depletion or even normal levels of the cerebral creatine pool are observed in female carriers with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> CRTR deficiency [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</a>].</p><p>Note: Complete lack of creatine in the presence of a normal choline and N-acetyl aspartate (NAA) levels in <sup>1</sup>H-MRS is unique to CCDS [<a class="bk_pop" href="#creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</a>].</p></div></div><div id="creatine.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CCDS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>GAMT or GATM</i> or a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (in males) of <i>SLC6A8</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK3794/table/creatine.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figcreatineTmoleculargenetictestinguse" rid-ob="figobcreatineTmoleculargenetictestinguse">Table 5</a>) using the following algorithm for guidance.</p><p><b>The diagnostic testing algorithm</b> for an individual with the listed clinical features and/or reduced creatine levels on brain <sup>1</sup>H-MRS (see <a class="figpopup" href="/books/NBK3794/figure/creatine.F1/?report=objectonly" target="object" rid-figpopup="figcreatineF1" rid-ob="figobcreatineF1">Figure 1</a>):</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figcreatineF1" co-legend-rid="figlgndcreatineF1"><a href="/books/NBK3794/figure/creatine.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figcreatineF1" rid-ob="figobcreatineF1"><img class="small-thumb" src="/books/NBK3794/bin/creatine-Image001.gif" src-large="/books/NBK3794/bin/creatine-Image001.jpg" alt="Figure 1. . Algorithm for diagnosis of the cerebral creatine deficiency syndromes." /></a><div class="icnblk_cntnt" id="figlgndcreatineF1"><h4 id="creatine.F1"><a href="/books/NBK3794/figure/creatine.F1/?report=objectonly" target="object" rid-ob="figobcreatineF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Algorithm for diagnosis of the cerebral creatine deficiency syndromes. Note: Urinary creatine/creatinine ratio and creatine uptake studies in cultured skin fibroblasts are often not informative in females with SLC6A8 deficiency; hence, molecular genetic <a href="/books/NBK3794/figure/creatine.F1/?report=objectonly" target="object" rid-ob="figobcreatineF1">(more...)</a></p></div></div><ul><li class="half_rhythm"><div class="half_rhythm">Measurement of guanidinoacetate (GAA), creatine, and creatinine in urine (<a class="figpopup" href="/books/NBK3794/table/creatine.T.urinary_metabolites_by_ccds_d/?report=objectonly" target="object" rid-figpopup="figcreatineTurinarymetabolitesbyccdsd" rid-ob="figobcreatineTurinarymetabolitesbyccdsd">Table 2</a>) and plasma (<a class="figpopup" href="/books/NBK3794/table/creatine.T.plasma_concentration_of_metab/?report=objectonly" target="object" rid-figpopup="figcreatineTplasmaconcentrationofmetab" rid-ob="figobcreatineTplasmaconcentrationofmetab">Table 3</a>)</div><ul><li class="half_rhythm"><div>If GAA concentration in urine is high, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>GAMT</i></div></li><li class="half_rhythm"><div>If GAA concentration in urine is low and plasma concentration of GAA is low, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>GATM</i></div></li><li class="half_rhythm"><div>If creatine/creatinine ratio in urine is high and GAA concentration in the urine is normal or slightly increased, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SLC6A8</i>.</div></li></ul><div class="half_rhythm">Note: Diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female probands requires <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SLC6A8</i> because they may have a normal creatine-to-creatinine ratio in urine and normal creatine content on brain <sup>1</sup>H-MRS [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">If molecular genetic test results are inconclusive (i.e., if sequence variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> are identified), GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>, <a class="bk_pop" href="#creatine.REF.verhoeven.2003.803">Verhoeven et al 2003</a>, <a class="bk_pop" href="#creatine.REF.verhoeven.2004.441">Verhoeven et al 2004</a>].</div><div class="half_rhythm">Note: Methods for testing GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts have been reported and may be helpful in the interpretation of variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> [<a class="bk_pop" href="#creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</a>, <a class="bk_pop" href="#creatine.REF.betsalel.2012.596">Betsalel et al 2012</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012b.433">Mercimek-Mahmutoglu et al 2012b</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.desroches.2015.2163">Desroches et al 2015</a>]. See <a href="#creatine.Molecular_Genetics">Molecular Genetics</a> for details.</div></li></ul><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b><i>GAMT</i>, <i>GATM</i>, and <i>SLC6A8</i> testing</b> is advised if biochemical features (e.g. creatine deficiency in brain <sup>1</sup>H-MRS) are suggestive of GAMT, AGAT, or CRTR deficiency.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Serial single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> is advised in the case of specific abnormalities in metabolites of creatine metabolism in body fluids (<a class="figpopup" href="/books/NBK3794/table/creatine.T.urinary_metabolites_by_ccds_d/?report=objectonly" target="object" rid-figpopup="figcreatineTurinarymetabolitesbyccdsd" rid-ob="figobcreatineTurinarymetabolitesbyccdsd">Tables 2-4</a>). Sequence analysis of the gene of interest is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> analysis if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>GAMT</i>, <i>GATM</i>, <i>SLC6A8</i>, and other genes of interest (see <a href="#creatine.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered in patients with developmental delay, intellectual disability, and/or epilepsy and/or movement disorder who did not undergo biochemical investigations for CCDS. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and mitochondrial sequencing may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of CCDS.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="creatine.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in CCDS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of CCDS Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3" id="hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3" id="hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GAMT</i></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39%&#x000a0;<sup>6</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%&#x000a0;<sup>6</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GATM</i></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>8</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%&#x000a0;<sup>8</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC6A8</i></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">56%&#x000a0;<sup>9</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95%&#x000a0;<sup>9,&#x000a0;10</sup></td><td headers="hd_h_creatine.T.molecular_genetic_testing_use_1_1_1_3 hd_h_creatine.T.molecular_genetic_testing_use_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%&#x000a0;<sup>11</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="creatine.TF.5.1"><p class="no_margin">See <a href="/books/NBK3794/#creatine.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.5.2"><p class="no_margin">See <a href="#creatine.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="creatine.TF.5.3"><p class="no_margin">In individuals with biochemical and/or enzymatic diagnosis of a specific CCDS</p></div></dd><dt>4. </dt><dd><div id="creatine.TF.5.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="creatine.TF.5.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="creatine.TF.5.6"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al [2014a]</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al [2014]</a></p></div></dd><dt>7. </dt><dd><div id="creatine.TF.5.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>8. </dt><dd><div id="creatine.TF.5.8"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al [2001]</a>, Battini et l [2002], <a class="bk_pop" href="#creatine.REF.battini.2006.828">Battini et al [2006]</a>, <a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al [2010]</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma [2010]</a>, <a class="bk_pop" href="#creatine.REF.ndika.2012.48">Ndika et al [2012]</a>, <a class="bk_pop" href="#creatine.REF.comeaux.2013.260">Comeaux et al [2013]</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al [2013]</a></p></div></dd><dt>9. </dt><dd><div id="creatine.TF.5.9"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</a></p></div></dd><dt>10. </dt><dd><div id="creatine.TF.5.10"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>11. </dt><dd><div id="creatine.TF.5.11"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.anselm.2006.214">Anselm et al [2006]</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2015.141">van de Kamp et al [2015]</a>, <a href="http://www.lovd.nl/SLC6A8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Leiden Open Variation Database</a></p></div></dd></dl></div></div></div></div></div><div id="creatine.Clinical_Characteristics"><h2 id="_creatine_Clinical_Characteristics_">Clinical Characteristics</h2><div id="creatine.Clinical_Description"><h3>Clinical Description</h3><p>Intellectual disability and seizures are common to all three creatine deficiency syndromes. Intellectual disability is associated with expressive speech delay and behavior disorder [<a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</a>].</p><div id="creatine.GAMT_Deficiency"><h4>GAMT Deficiency</h4><p>Approximately 110 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been published either as single case reports or small groups of cases [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</a>, <a class="bk_pop" href="#creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</a>, <a class="bk_pop" href="#creatine.REF.dhar.2009.38">Dhar et al 2009</a>, <a class="bk_pop" href="#creatine.REF.engelke.2009.538">Engelke et al 2009</a>, <a class="bk_pop" href="#creatine.REF.orourke.2009.404">O'Rourke et al 2009</a>, <a class="bk_pop" href="#creatine.REF.sempere.2009a.745">Sempere et al 2009a</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010b.s101">Mercimek-Mahmutoglu et al 2010b</a>, <a class="bk_pop" href="#creatine.REF.cheillan.2012.96">Cheillan et al 2012</a>, <a class="bk_pop" href="#creatine.REF.nasrallah.2012.427">Nasrallah et al 2012</a>, <a class="bk_pop" href="#creatine.REF.comeaux.2013.260">Comeaux et al 2013</a>, <a class="bk_pop" href="#creatine.REF.elgharbawy.2013.215">El-Gharbawy et al 2013</a>, <a class="bk_pop" href="#creatine.REF.viau.2013.255">Viau et al 2013</a>, <a class="bk_pop" href="#creatine.REF.akiyama.2014.65">Akiyama et al 2014</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p>A review of 80 individuals with GAMT deficiency revealed that intellectual disability and epilepsy are the most consistent clinical features [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>]. About 60% of individuals with GAMT deficiency have a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> characterized by severe intellectual disability, intractable epilepsy, and movement disorder [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p><b>Onset</b> of the first clinical manifestations ranges from early infancy (age 3-6 months) to age three years.</p><p><b>Intellectual disability,</b> the most consistent clinical manifestation, is present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The severity of intellectual disability ranges from mild to severe. About 60% of individuals with GAMT deficiency have severe developmental delay or intellectual disability [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p><b>Language.</b> Variable expressive language deficits were reported in two sibs with GAMT deficiency: the index case spoke fewer than ten words whereas her younger sister spoke in short sentences at age 13 years [<a class="bk_pop" href="#creatine.REF.orourke.2009.404">O'Rourke et al 2009</a>].</p><p><b>Seizures,</b> the second most consistent manifestation in GAMT deficiency, are observed in about 78% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Seizure types include myoclonic, generalized tonic-clonic, partial complex, head nodding, and atonic seizures. Seizure severity ranges from occasional seizures to seizures that are non-responsive to various antiepileptic drugs [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p><b>Movement disorders,</b> observed in about 30% of individuals, are mainly chorea, athetosis, dystonia, or ataxia [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>]. Pathologic signal intensities in the basal ganglia in brain MRI are observed in individuals with or without a movement disorder [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>]. The onset is usually before age 12 years; however, recently a young woman with GAMT deficiency was reported to have onset of movement disorder (including ballistic and dystonic movements) at age 17 years [<a class="bk_pop" href="#creatine.REF.orourke.2009.404">O'Rourke et al 2009</a>].</p><p><b>A behavior disorder</b> (e.g., hyperactivity, autism, or self-injurious behavior) is reported in about 77% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>].</p></div><div id="creatine.AGAT_Deficiency"><h4>AGAT Deficiency</h4><p>Fourteen individuals from seven families have been diagnosed with AGAT deficiency [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>, <a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>, <a class="bk_pop" href="#creatine.REF.battini.2006.828">Battini et al 2006</a>, <a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma 2010</a>, <a class="bk_pop" href="#creatine.REF.ndika.2012.48">Ndika et al 2012</a>, <a class="bk_pop" href="#creatine.REF.comeaux.2013.260">Comeaux et al 2013</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al 2013</a>].</p><p><b>Intellectual disability,</b> the most consistent clinical manifestation, is present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The severity of intellectual disability ranges from mild to moderate.</p><p><b>Seizures,</b> observed in only 9% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, were occasional and associated with fever.</p><p><b>Muscle weakness or hypotonia</b> was observed in 67% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma 2010</a>, <a class="bk_pop" href="#creatine.REF.ndika.2012.48">Ndika et al 2012</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al 2013</a>].</p><p><b>Failure to thrive</b> was reported in two sibs [<a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>].</p><p><b>A behavior disorder</b> was present in 27% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b>Movement disorders</b> were not reported in any <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="creatine.CRTR_Deficiency"><h4>CRTR Deficiency</h4><p><b>Affected Males</b></p><p>Since the first description of SLC6A8 deficiency by <a class="bk_pop" href="#creatine.REF.salomons.2001.1497">Salomons et al [2001]</a>, 85 families comprising a total of 101 male individuals with an <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported in a single international registry study [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, and behavior disorder that may become more marked during the course of the disease.</p><p><b>The age at diagnosis</b> ranges from one to 66 years indicating that life expectancy can be normal. Now that the disorder is reasonably well described and diagnostic testing is more widely available, it is anticipated that diagnosis will mainly occur within the first three years of life.</p><p><b>Intellectual disability</b> was present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male individuals ranging from mild to severe: 85% of affected males had mild to moderate intellectual disability up to age four years; 75% of affected males older than age 18 years had severe intellectual disability [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>]. One adult had progressive cognitive dysfunction [<a class="bk_pop" href="#creatine.REF.kleefstra.2005.379">Kleefstra et al 2005</a>].</p><p><b>Speech-language disorder.</b> Speech development was delayed in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. First words were at a mean age of 3.1 years (age range: 9 months to 10 years). In affected males older than age ten years, 14% had no speech development, 55% were able to speak single words, and 31% were able to speak in sentences [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p>A neuropsychological profile in four <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> boys from two unrelated families from the Netherlands revealed a semantic-pragmatic language disorder (difficulty in understanding the meaning of words) with oral dyspraxia [<a class="bk_pop" href="#creatine.REF.mancini.2005.288">Mancini et al 2005</a>].</p><p><b>Seizures</b> were present in 59% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male individuals. The most common seizure type was generalized tonic-clonic and simple or complex partial seizures with or without secondary generalization. Absence and myoclonic seizures were rare. Age of seizure onset was between one and 21 years [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</a>]. Fewer than ten patients with intractable epilepsy have been reported [<a class="bk_pop" href="#creatine.REF.mancardi.2007.1211">Mancardi et al 2007</a>, <a class="bk_pop" href="#creatine.REF.fons.2009.2168">Fons et al 2009</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p><b>Movement disorder.</b> Wide-based gait or ataxia and dystonia or athetosis were reported in 29% and 11% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males respectively [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p><b>Behavior disorder.</b> Behavior disorder was reported in 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. The most common behavior disorders were attention deficit and/or hyperactivity (55%) and autistic features (41%). Other behavior disorders reported in affected males include social anxiety or shyness (20%), stereotypic behavior (20%), impulsive behavior (27%), aggressive behavior (19%), self-injurious behavior (10%), and obsessive-compulsive behavior (8%) [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p><b>Other neurologic clinical features.</b> Hypotonia was present in 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. Spasticity was reported in 26% of affected males. Four individuals had mild (sensorial-neural) hearing loss. Nine affected males were reported with strabismus or bilateral abducens nerve palsy. Myopathic face, ptosis, joint laxity (likely secondary to the hypotonia), and decreased muscle bulk were also reported [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p><b>Other non-neurologic clinical features</b></p><ul><li class="half_rhythm"><div><b>Dysmorphic features</b> including microcephaly, broad forehead, midface retrusion, high palate, short nose, prominent nasal bridge, ear differences (underfolded helices, large ears, and/or cupped ears), deeply set eyes, fifth finger clinodactyly, and slender body build were reported in 45% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males [<a class="bk_pop" href="#creatine.REF.anselm.2006.214">Anselm et al 2006</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</a>].</div></li><li class="half_rhythm"><div><b>Gastrointestinal</b>
<b>findings</b> including failure to thrive, vomiting, constipation, ileus likely secondary to constipation, hepatitis, gastric and duodenal ulcers, and hiatal hernia (which may or may not be related to CRTR deficiency) were reported in 35% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</div></li><li class="half_rhythm"><div><b>Cardiac features.</b> One boy with CRTR deficiency developed multiple premature ventricular contractions in his second year [<a class="bk_pop" href="#creatine.REF.anselm.2008.1642">Anselm et al 2008</a>]. Two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males with mild cardiomyopathy were reported [<a class="bk_pop" href="#creatine.REF.puusepp.2010.s5">Puusepp et al 2010</a>]. One affected male had long QT syndrome [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</div></li><li class="half_rhythm"><div><b>Medical concerns in adulthood.</b> Twenty-one of 101 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males were adults (age &#x0003e;18 years). Adults affected with CRTR deficiency had intellectual disability ranging from moderate to severe [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</a>]. They presented with myopathic face, ptosis, external ophthalmoplegia, or parkinsonism. Chronic constipation leading to megacolon, ileus or bowel perforation, and/or gastric or duodenal ulcer disease have been reported in some adults [<a class="bk_pop" href="#creatine.REF.hahn.2002.1349">Hahn et al 2002</a>, <a class="bk_pop" href="#creatine.REF.kleefstra.2005.379">Kleefstra et al 2005</a>, <a class="bk_pop" href="#creatine.REF.sempere.2009b.s91">Sempere et al 2009b</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</div></li></ul><p><b>Heterozygous Females</b></p><p>Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for their family-specific <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are either asymptomatic or have mild intellectual disability [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</a>]. There was no clinical correlation between skewed X-inactivation in favor of the pathogenic variant <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and severity of clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. There was no significant statistical correlation between intellectual ability and cerebral creatine level on brain <sup>1</sup>H-MRS [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</a>]. A female with mild intellectual disability, intractable epilepsy, and behavior problems (a phenotype similar to <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males) did not have evidence of skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> in peripheral blood cells; tissue-specific skewed X- chromosome inactivation in the brain could explain her severe neurologic findings [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</a>].</p></div></div><div id="creatine.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are known for any of the CCDS.</p><p>Of note, the phenotypes of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the two most common <i>GAMT</i> pathogenic variants (<a class="figpopup" href="/books/NBK3794/table/creatine.T.selected_gamt_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="figcreatineTselectedgamtpathogenicvari" rid-ob="figobcreatineTselectedgamtpathogenicvari">c.59G&#x0003e;C</a> and <a class="figpopup" href="/books/NBK3794/table/creatine.T.selected_gamt_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="figcreatineTselectedgamtpathogenicvari" rid-ob="figobcreatineTselectedgamtpathogenicvari">c.327G&#x0003e;A</a>) range from mild to severe.</p></div><div id="creatine.Prevalence"><h3>Prevalence</h3><p><b>GAMT deficiency.</b> Approximately 110 individuals with GAMT deficiency have been diagnosed worldwide.</p><p>The estimated incidence of GAMT deficiency in the general population ranges from 1:2,640,000 to 1:550,000 [<a class="bk_pop" href="#creatine.REF.desroches.2015.2163">Desroches et al 2015</a>]. This is in agreement with information from pilot <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> programs for GAMT deficiency, which screened approximately 1,000,000 newborns; to date none of the newborns has a confirmed diagnosis of GAMT deficiency [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012b.433">Mercimek-Mahmutoglu et al 2012b</a>, <a class="bk_pop" href="#creatine.REF.pasquali.2014.231">Pasquali et al 2014</a>, <a class="bk_pop" href="#creatine.REF.pitt.2014.303">Pitt et al 2014</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p>In contrast, the estimated incidence of GAMT deficiency in the Utah newborn population was 1:114,072 [<a class="bk_pop" href="#creatine.REF.viau.2013.255">Viau et al 2013</a>].</p><p>Smaller studies of individuals with neurologic disease or severe intellectual disability found GAMT deficiency present in 0.094% and 1.1% respectively [<a class="bk_pop" href="#creatine.REF.caldeira_ara_jo.2005.122">Caldeira Ara&#x000fa;jo et al 2005</a>, <a class="bk_pop" href="#creatine.REF.cheillan.2012.96">Cheillan et al 2012</a>].</p><p><b>AGAT deficiency.</b> No prevalence studies have been performed to date.</p><p><b>CRTR deficiency.</b> CRTR deficiency has been studied in many cohorts ranging from 49 to 4,426 individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> or non-familial intellectual disability. Recently these studies were summarized by <a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al [2014]</a>:</p><ul><li class="half_rhythm"><div>Three studies of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> families found CRTR deficiency in eight out of 408 cases, for a prevalence of 2.0% (CI 0.6-3.3);</div></li><li class="half_rhythm"><div>Six studies of cohorts with intellectual disability found CRTR deficiency in 15 out of 1,102 cases, for a prevalence of 1.4% (CI 0.7-2.0).</div></li></ul><p>These studies together with two miscellaneous cohorts resulted in 28 positive cases out of 7,218, for a prevalence of 0.4% (CI 0.2-0.5).</p></div></div><div id="creatine.Genetically_Related_Allelic_Dis"><h2 id="_creatine_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>GAMT</i>, <i>GATM</i>, or <i>SLC6A8.</i></p></div><div id="creatine.Differential_Diagnosis"><h2 id="_creatine_Differential_Diagnosis_">Differential Diagnosis</h2><p>Secondary (cerebral) creatine deficiencies have been observed in <a href="/books/n/gene/args-aciduria/">argininosuccinate lyase deficiency</a> (ASL) and argininosuccinate synthetase deficiency (<a href="/books/n/gene/ctlm/">citrullinemia type 1</a>) [<a class="bk_pop" href="#creatine.REF.van_spronsen.2006.274">van Spronsen et al 2006</a>], ornithine aminotransferase deficiency (gyrate atrophy of the choroid and retina) [<a class="bk_pop" href="#creatine.REF.n_ntosalonen.1999.303">N&#x000e4;nto-Salonen et al 1999</a>], and &#x00394;(1)-pyrroline-5-carboxylate synthetase (P5CS) deficiency [<a class="bk_pop" href="#creatine.REF.martinelli.2012.761">Martinelli et al 2012</a>].</p><p><a class="bk_pop" href="#creatine.REF.boenzi.2012.647">Boenzi et al [2012]</a> measured plasma creatine levels in individuals with <a href="/books/n/gene/otc-def/">ornithine transcarbamylase</a> (OTC), <a href="/books/n/gene/ctlm/">argininosuccinate synthetase</a> (ASS), and <a href="/books/n/gene/args-aciduria/">argininosuccinate lyase</a> (ASL) deficiencies; <a href="/books/n/gene/hhhs/">hyperammonemia, hyperornithinemia, homocitrullinuria (HHH) syndrome</a>; and <a href="/books/n/gene/lpi/">lysinuric protein intolerance</a> (LPI). Individuals with OTC and ASS deficiencies and HHH syndrome showed significant reduction of plasma creatine concentration, whereas individuals with ASL deficiency and LPI had high plasma creatine levels.</p><p>These disorders should be considered in individuals with partial cerebral creatine deficiency in the brain detected by <sup>1</sup>H-MRS, who have normal concentrations of guanidinoacetate (GAA) in the urine, plasma, and CSF and a normal creatine-to-creatinine ratio in urine.</p></div><div id="creatine.Management"><h2 id="_creatine_Management_">Management</h2><div id="creatine.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To assess the extent of disease and needs of an individual diagnosed with CCDS the following investigations should be performed:</p><ul><li class="half_rhythm"><div>Detailed neurologic clinical evaluation for the degree of developmental delay or intellectual disability, epilepsy, movement disorder, and behavior problems</div></li><li class="half_rhythm"><div>Neuropsychological assessment of cognition and speech</div></li><li class="half_rhythm"><div>Video documentation of movement disorder</div></li><li class="half_rhythm"><div>EEG, if any clinical seizures</div></li><li class="half_rhythm"><div>Prior to initiation of creatine monohydrate supplementation, glomerular filtration rate (GFR) for baseline assessment of kidney function</div></li><li class="half_rhythm"><div>Baseline determination of cerebral creatine level by brain <sup>1</sup>H-MRS to document creatine deficiency [<a class="bk_pop" href="#creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</a>, <a class="bk_pop" href="#creatine.REF.schulze.2001.413">Schulze et al 2001</a>]</div></li><li class="half_rhythm"><div>ECG and echocardiogram for cardiac involvement</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="creatine.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Occupational therapy, physiotherapy, and speech-language therapy for developmental delay by physiotherapist, occupational therapist, speech-language therapist</div></li><li class="half_rhythm"><div>Behavior therapy for behavior problems by developmental pediatrician</div></li><li class="half_rhythm"><div>Seizure management with antiepileptic drugs by epilepsy specialist</div></li><li class="half_rhythm"><div>Treatment of movement disorder by movement disorder specialist</div></li></ul><div id="creatine.GAMT_Deficiency_1"><h4>GAMT Deficiency</h4><p>Treatment of GAMT deficiency aims to replenish cerebral creatine levels by supplementation with creatine monohydrate and to decrease accumulation of neurotoxic GAA in the central nervous system by ornithine supplementation and protein- or arginine-restricted diet [<a class="bk_pop" href="#creatine.REF.schulze.2001.413">Schulze et al 2001</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>]. Creatine monohydrate and ornithine supplementation decrease GAA accumulation by competitive inhibition of AGAT enzyme activity. A decrease in the level of GAA in cerebrospinal fluid was reported in two individuals with GAMT deficiency treated with creatine monohydrate and ornithine supplementation and with arginine restriction [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012a.155">Mercimek-Mahmutoglu et al 2012a</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</a>].</p><p>Treatment is as follows:</p><ul><li class="half_rhythm"><div>Creatine monohydrate in oral doses ranging from 400-800 mg/kg BW/day in three to six divided doses [<a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>]</div></li><li class="half_rhythm"><div>Supplementation of ornithine ranging from 400-800 mg/kg BW/day. Administration of ornithine is divided into three to six daily doses [<a class="bk_pop" href="#creatine.REF.schulze.1998.606">Schulze et al 1998</a>, <a class="bk_pop" href="#creatine.REF.schulze.2001.413">Schulze et al 2001</a>].</div></li><li class="half_rhythm"><div>Dietary restriction of arginine to 15-25 mg/kg/day that corresponds to 0.4-0.7 g/kg/day protein intake [<a class="bk_pop" href="#creatine.REF.schulze.1998.606">Schulze et al 1998</a>, <a class="bk_pop" href="#creatine.REF.schulze.2001.413">Schulze et al 2001</a>, <a class="bk_pop" href="#creatine.REF.schulze.2003.248">Schulze et al 2003</a>]</div><ul><li class="half_rhythm"><div>To prevent protein malnutrition, essential amino acid medical formula should be supplemented (0.5-0.8g/kg/day). Available databases (e.g., the US Department of Agriculture National Nutrient Database) can be used to determine exact arginine content of foods to allow precise calculation of daily arginine intake in individuals with GAMT deficiency [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012a.155">Mercimek-Mahmutoglu et al 2012a</a>].</div></li><li class="half_rhythm"><div>Because of the challenges involved in understanding arginine restriction, reading dietary labels, and calculating arginine intake (particularly since arginine content is not always indicated), many centers use protein restriction instead [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012a.155">Mercimek-Mahmutoglu et al 2012a</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</a>].</div></li></ul></li></ul><p><b>Treatment outcome of symptomatic individuals with GAMT deficiency</b></p><ul><li class="half_rhythm"><div><b>Developmental delay and intellectual disability</b> improved only in 21% of the individuals. None of the individuals achieved normal development or cognitive functions on treatment [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Seizures.</b> In 18% of individuals seizures were eliminated; in 49% seizure frequency decreased; 33% of individuals had no improvement in seizures [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Movement disorder.</b> Improvement was seen in 60% of individuals; in 40% of individuals, there was no change in the movement disorder [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</div></li></ul><p><b>Treatment outcome of asymptomatic individuals with GAMT deficiency</b></p><ul><li class="half_rhythm"><div>Normal neurodevelopmental outcome has been reported in three individuals with GAMT deficiency who were diagnosed and treated in the neonatal period based on a positive family history of GAMT deficiency in an older sib [<a class="bk_pop" href="#creatine.REF.schulze.2006.719">Schulze et al 2006</a>, <a class="bk_pop" href="#creatine.REF.elgharbawy.2013.215">El-Gharbawy et al 2013</a>, <a class="bk_pop" href="#creatine.REF.viau.2013.255">Viau et al 2013</a>].</div></li><li class="half_rhythm"><div>Another asymptomatic sib treated from age eight days showed developmental delay and hypotonia at age 11 months. The authors suggested compliance problems in this family [<a class="bk_pop" href="#creatine.REF.dhar.2009.38">Dhar et al 2009</a>].</div></li></ul></div><div id="creatine.AGAT_Deficiency_1"><h4>AGAT Deficiency</h4><p>Treatment of AGAT deficiency aims to replenish cerebral creatine levels by supplementation with creatine monohydrate in oral doses ranging from 400 to 800 mg/kg BW/day in three to six divided doses.</p><p><b>Treatment outcome of symptomatic individuals with AGAT deficiency.</b> Treatment outcome results were reported in 11 individuals with AGAT deficiency [<a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>, <a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma 2010</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al 2013</a>]. If initiation of treatment was after age ten years, no improvement in cognitive function or intellectual disability was seen [<a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>, <a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma 2010</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al 2013</a>]. Normal cognitive function was reported in a female whose treatment was initiated before age two years [<a class="bk_pop" href="#creatine.REF.ndika.2012.48">Ndika et al 2012</a>]. Muscle weakness was improved in all individuals treated with creatine monohydrate [<a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al 2010</a>, <a class="bk_pop" href="#creatine.REF.verma.2010.186">Verma 2010</a>, <a class="bk_pop" href="#creatine.REF.nouioua.2013.670">Nouioua et al 2013</a>].</p><p><b>Treatment outcome of asymptomatic individuals with AGAT deficiency.</b> An asymptomatic sib treated from age four months with creatine monohydrate supplementation therapy had normal neurodevelopment at age 18 months; in contrast, his sisters had already shown signs of developmental delay at this age [<a class="bk_pop" href="#creatine.REF.battini.2006.828">Battini et al 2006</a>].</p></div><div id="creatine.CRTR_Deficiency_1"><h4>CRTR Deficiency</h4><p>The goal of treatment is to replenish cerebral creatine levels. Treatment of both males and females with CRTR deficiency with creatine-monohydrate was not successful [<a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</a>]. Only one <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female with learning disability and mildly decreased creatine concentration on brain <sup>1</sup>H-MRS showed mild improvement on neuropsychological testing after 18 weeks of treatment with creatine-monohydrate (250-750 mg/kg/day) [<a class="bk_pop" href="#creatine.REF.cecil.2001.401">Cecil et al 2001</a>]. Additionally, combined arginine and glycine supplementation therapy successfully treated intractable epilepsy in a female with CRTR deficiency [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</a>].</p><p>Since the enzymes for creatine biosynthesis are present in the brain [<a class="bk_pop" href="#creatine.REF.braissant.2008.230">Braissant &#x00026; Henry 2008</a>], individuals with CRTR deficiency have been treated with L-arginine and L-glycine, precursors in the biosynthesis of creatine.</p><p>Treatment has included:</p><ul><li class="half_rhythm"><div>Creatine monohydrate 100-200 mg/kg BW/day in 3 doses</div></li><li class="half_rhythm"><div>Arginine (hydrochloride or base) 400 mg/kg BW/day in 3 doses</div></li><li class="half_rhythm"><div>Glycine 150 mg/kg BW/day in 3 doses</div></li></ul><p>The authors recommend that all three of the supplements listed above be started together in new patients &#x02013; especially in early childhood &#x02013; to slow disease progression. The clinical effectiveness of treatment with three supplements has not been confirmed.</p><p><b>Treatment outcome of individuals with CRTR deficiency.</b> To date 22 males and three females with CRTR deficiency have been treated with L-arginine with or without glycine supplementation [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</a>].</p><ul><li class="half_rhythm"><div>In some patients improvements were reported, but in general results appeared to be discouraging and cerebral creatine was not restored [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</a>].</div></li><li class="half_rhythm"><div>Four males and two females with CRTR deficiency treated for 42 months with creatine, arginine, and glycine showed increased muscle mass and improved gross motor skills [<a class="bk_pop" href="#creatine.REF.valayannopoulos.2012.151">Valayannopoulos et al 2012</a>].</div></li><li class="half_rhythm"><div>Nine males with CRTR deficiency showed improvement in locomotor and personal social IQ subscales [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2012.141">van de Kamp et al 2012</a>].</div></li><li class="half_rhythm"><div>Combined arginine and glycine supplementation therapy successfully treated intractable epilepsy in a female with CRTR deficiency [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</a>].</div></li></ul></div></div><div id="creatine.Prevention_of_Primary_Manifesta"><h3>Prevention of Primary Manifestations</h3><p>See <a href="#creatine.Treatment_of_Manifestations">Treatment of Manifestations</a>.</p></div><div id="creatine.Surveillance"><h3>Surveillance</h3><p>For patients undergoing treatment:</p><ul><li class="half_rhythm"><div>Determination of cerebral creatine level by in vivo <sup>1</sup>H-MRS should be performed:</div><ul><li class="half_rhythm"><div>For individuals with GAMT and AGAT deficiency to monitor cerebral creatine levels during creatine supplementation therapy;</div></li><li class="half_rhythm"><div>For individuals with CRTR deficiency to monitor cerebral creatine levels for the assessment of treatment outcome [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010b.s101">Mercimek-Mahmutoglu et al 2010b</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2012.141">van de Kamp et al 2012</a>].</div></li></ul></li><li class="half_rhythm"><div>For GAMT deficiency: growth and nutritional status (plasma GAA levels, amino acids, ammonia, protein, albumin, pre-albumin levels) should be monitored every three to six months.</div></li><li class="half_rhythm"><div>For CRTR deficiency: plasma GAA levels and plasma amino acids should be monitored every three to six months as high-dose arginine and glycine supplementation can result in increased GAA levels.</div></li><li class="half_rhythm"><div>Repeat GFR annually for assessment of kidney function while on creatine supplementation therapy to detect possible creatine-associated nephropathy [<a class="bk_pop" href="#creatine.REF.barisic.2002.157">Barisic et al 2002</a>].</div></li><li class="half_rhythm"><div>Perform neuropsychological assessment of cognitive functions and speech.</div></li></ul></div><div id="creatine.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate neonates at-risk for GAMT deficiency or AGAT deficiency to allow for early diagnosis and treatment.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known;</div></li><li class="half_rhythm"><div>Biochemical genetic testing if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#creatine.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to evaluation of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="creatine.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Transport of dodecyl creatine ester incorporated into lipid nanocapsules (LNCs) was investigated using an in vitro cell-based blood-brain barrier model. It has been shown that these LNCs can cross the blood-brain barrier and enter brain endothelial cells. In human fibroblasts with deficient SLC6A8 protein function, all or part of the dodecyl creatine ester was released from the LNCs and biotransformed to creatine [<a class="bk_pop" href="#creatine.REF.trotierfaurion.2015.185">Trotier-Faurion et al 2015</a>].</p><p>A brain-specific <i>Slc6a8</i> knockout mouse was successfully treated with the cyclocreatine, which is a creatine analog. Brain cyclocreatine and cyclocreatine phosphate were detected on cyclocreatine treatment in the brain-specific <i>Slc6a8</i> knockout mice at nine weeks of cyclocreatine treatment compared to the creatine and placebo treatment in the same mice. Cyclocreatine-treated brain-specific <i>Slc6a8</i> knockout mice showed improvements in cognitive abilities using novel object recognition and spatial learning and memory tests. Thus, cyclocreatine appears promising as a potential therapy for CRTR deficiency. Clinical trials are underway to prove its use in individuals with CRTR deficiency.</p><p>Search <a href="http://www.ClinicalTrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="creatine.Genetic_Counseling"><h2 id="_creatine_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="creatine.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>GAMT deficiency and AGAT deficiency are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>CRTR deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="creatine.Risk_to_Family_Members__Autosom"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a child with GAMT or AGAT deficiency are obligate heterozygotes (i.e., carriers of one <i>GAMT</i> or <i>GATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an individual with GAMT or AGAT deficiency has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk that s/he is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>GAMT</i> or <i>GATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> To date, individuals with GAMT or AGAT deficiency have not reproduced.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>GAMT</i> or <i>GATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="creatine.Carrier_Detection"><h3>Carrier Detection</h3><p><b>Molecular genetic testing.</b> Carrier testing for at-risk relatives requires prior identification of the <i>GAMT</i> or <i>GATM</i> pathogenic variants in the family.</p></div><div id="creatine.Risk_to_Family_Members__XLinked"><h3>Risk to Family Members &#x02013; X-Linked Inheritance</h3><p><b>Parents of a Proband</b></p><ul><li class="half_rhythm"><div>The father of a male with CRTR deficiency will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: if a woman has more than one affected child and no other affected relatives and if the <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>; 7% of mothers in a retrospective study of 85 families had somatic/germline mosaicism [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), several possibilities regarding his mother's genetic status need to be considered:</div><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and his mother is not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the variant [<a class="bk_pop" href="#creatine.REF.salomons.2003.309">Salomons et al 2003</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</a>]. <i>SLC6A8</i> pathogenic variants occurred <i>de novo</i> in 30% of the individuals with CRTR deficiency in the <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</a> retrospective study.</div></li><li class="half_rhythm"><div>His mother has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, either (a) as a "<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant" (i.e., present at the time of her conception and therefore in every cell of her body); or (b) as "<a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>" (i.e., present in some of her germ cells only) [<a class="bk_pop" href="#creatine.REF.betsalel.2008.183">Betsalel et al 2008</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</div></li><li class="half_rhythm"><div>His mother is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></li><li class="half_rhythm"><div>Heterozygous mothers may have a history of learning disability or mild intellectual disability or seizures [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</a>] (see Clinical Description, <a href="#creatine.CRTR_Deficiency">CRTR Deficiency</a>, <b>Heterozygous Females</b>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs depends on the genetic status of the mother.</div></li><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and may develop clinical findings related to the disorder (see Clinical Description, <a href="#creatine.CRTR_Deficiency">CRTR Deficiency</a>, <b>Heterozygous Females</b>).</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#creatine.REF.betsalel.2008.183">Betsalel et al 2008</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> No <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male has reproduced.</p><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the aunts' offspring, depending on their gender, may be at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the pathogenic variant or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>In one family, a maternal aunt with verbal memory deficit and a mild confrontational naming weakness was described [<a class="bk_pop" href="#creatine.REF.degrauw.2003.45">deGrauw et al 2003</a>].</div></li></ul></div><div id="creatine.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may develop clinical findings related to the disorder (see Clinical Description, <a href="#creatine.CRTR_Deficiency">CRTR Deficiency</a>, <b>Heterozygous Females</b>). (2) Identification of female carriers requires either (a) prior identification of the <i>SLC6A8</i> pathogenic variant in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div><div id="creatine.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#creatine.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or are at risk of being heterozygous.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="creatine.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>GAMT</i>, <i>GATM</i>, or <i>SLC6A8</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing or for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical genetic testing.</b> Prenatal diagnosis for pregnancies at increased risk for GAMT deficiency is possible by analysis of guanidinoacetate and creatine in amniotic fluid. Amniocentesis for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> was performed at 15 weeks' gestation in the mother of a child age ten years with GAMT deficiency. Guanidinoacetate was 11.43 &#x003bc;mol/L (normal range for 15 weeks of amenorrhea was 2.96 &#x000b1; 0.70 &#x003bc;mol/L) [<a class="bk_pop" href="#creatine.REF.cheillan.2006.775">Cheillan et al 2006</a>].</p></div></div><div id="creatine.Resources"><h2 id="_creatine_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association for Creatine Deficiencies </b></div><div>1024 Bayside Drive</div><div>Suite 532</div><div>Newport Beach CA 92660</div><div><b>Email:</b> kim@creatineinfo.org</div><div><a href="http://creatineinfo.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.creatineinfo.org</a></div></li><li class="half_rhythm"><div><b>American Association on Intellectual and Developmental Disabilities (AAIDD)</b></div><div>501 3rd Street Northwest</div><div>Suite 200</div><div>Washington DC 20001</div><div><b>Phone:</b> 202-387-1968</div><div><b>Fax:</b> 202-387-2193</div><div><b>Email:</b> sis@aaidd.org</div><div><a href="http://www.aaidd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aaidd.org</a></div></li><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Intellectual Disability</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>National Center on Birth Defects and Developmental Disabilities</b></div><div>1600 Clifton Road</div><div>MS E-87</div><div>Atlanta GA 30333</div><div><b>Phone:</b> 800-232-4636 (toll-free); 888-232-6348 (TTY)</div><div><b>Email:</b> cdcinfo@cdc.gov</div><div><a href="http://www.cdc.gov/ncbddd/dd/ddmr.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Intellectual Disability</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=guanidinoacetatemethyltransferasedeficiency" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Guanidinoacetate methyltransferase deficiency</a></div></li><li class="half_rhythm"><div><b>Association for Creatine Deficiencies Patient Registry</b></div><div><a href="http://creatineinfo.org/patient-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.creatineinfo.org/patient-registry</a></div></li></ul></div><div id="creatine.Molecular_Genetics"><h2 id="_creatine_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="creatine.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Creatine Deficiency Syndromes: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_creatine.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_creatine.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_creatine.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_creatine.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_creatine.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_creatine.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_creatine.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2593" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GAMT</i></a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2593" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q14353" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Guanidinoacetate N-methyltransferase</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/GAMT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GAMT @ LOVD</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GAMT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GAMT</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GAMT[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GAMT</a></td></tr><tr><td headers="hd_b_creatine.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2628" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GATM</i></a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2628" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P50440" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Glycine amidinotransferase, mitochondrial</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/GATM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATM @ LOVD</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GATM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATM</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GATM[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATM</a></td></tr><tr><td headers="hd_b_creatine.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6535" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC6A8</i></a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6535" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P48029" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sodium- and chloride-dependent creatine transporter 1</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/SLC6A8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A8 @ LOVD</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC6A8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A8</a></td><td headers="hd_b_creatine.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC6A8[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A8</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="creatine.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="creatine.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Creatine Deficiency Syndromes (<a href="/omim/300036,300352,601240,602360,612718,612736" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300036" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300036</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, CREATINE), MEMBER 8; SLC6A8</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300352" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300352</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601240" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601240</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GUANIDINOACETATE METHYLTRANSFERASE; GAMT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602360" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602360</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612718" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612718</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612736" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612736</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</td></tr></tbody></table></div></div><div id="creatine.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Creatine is synthesized by one of two enzymatic reactions:</p><ul><li class="half_rhythm"><div>Transfer of the amidino group from arginine to glycine, yielding guanidinoacetic acid and catalyzed by L-arginine:glycine amidinotransferase (also known as glycine amidinotransferase, mitochondrial, AGAT, or GATM)</div></li><li class="half_rhythm"><div>Methylation of the amidino group in the guanidinoacetic acid molecule by S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase (also known as guanidinoacetate N-methyltransferase or GAMT)</div></li></ul><p>Creatine is synthesized primarily in the kidney and pancreas, which have high AGAT activity, and in liver, which has high GAMT activity. Both genes and enzymes have been detected in brain as well [<a class="bk_pop" href="#creatine.REF.braissant.2008.230">Braissant &#x00026; Henry 2008</a>].</p><p>Synthesized creatine is transported via the bloodstream to the organs of utilization (mainly muscle and brain), where it is taken up via sodium- and chloride-dependent creatine transporter 1 (SLC6A8 protein) (<a class="figpopup" href="/books/NBK3794/figure/creatine.F2/?report=objectonly" target="object" rid-figpopup="figcreatineF2" rid-ob="figobcreatineF2">Figure 2</a>) [<a class="bk_pop" href="#creatine.REF.wyss.2000.1107">Wyss &#x00026; Kaddurah-Daouk 2000</a>]. This protein is predominantly expressed in skeletal muscle and kidney, but also found in brain, heart, colon, testis, and prostate. The creatine-phosphocreatine shuttle has a key function in the maintenance of the energy supply to skeletal and cardiac muscle. Muscle cells do not synthesize creatine, but take it up via a special sodium-dependent transporter, the creatine transporter.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figcreatineF2" co-legend-rid="figlgndcreatineF2"><a href="/books/NBK3794/figure/creatine.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figcreatineF2" rid-ob="figobcreatineF2"><img class="small-thumb" src="/books/NBK3794/bin/creatine-Image002.gif" src-large="/books/NBK3794/bin/creatine-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndcreatineF2"><h4 id="creatine.F2"><a href="/books/NBK3794/figure/creatine.F2/?report=objectonly" target="object" rid-ob="figobcreatineF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Schema illustrating (1) CREATINE SYNTHESIS that occurs mainly in liver, pancreas, and kidney; (2) CREATINE UPTAKE into muscle and brain by the creatine transporter (CRTR); and (3) non-enzymatic conversion of creatine to creatinine for CREATININE EXCRETION <a href="/books/NBK3794/figure/creatine.F2/?report=objectonly" target="object" rid-ob="figobcreatineF2">(more...)</a></p></div></div><p>If molecular genetic test results are inconclusive (i.e., if sequence variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> are identified), GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>, <a class="bk_pop" href="#creatine.REF.verhoeven.2003.803">Verhoeven et al 2003</a>, <a class="bk_pop" href="#creatine.REF.verhoeven.2004.441">Verhoeven et al 2004</a>]. In addition, functional testing has been performed for many <i>GAMT</i> and <i>SLC6A8</i> variants [<a class="bk_pop" href="#creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</a>, <a class="bk_pop" href="#creatine.REF.betsalel.2012.596">Betsalel et al 2012</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2012b.433">Mercimek-Mahmutoglu et al 2012b</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.desroches.2015.2163">Desroches et al 2015</a>].</p><div id="creatine.GAMT"><h4><i>GAMT</i></h4><p><b>Gene structure.</b>
<i>GAMT</i> comprises six exons spanning about 5 kb, forming an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> of 711 nucleotides. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK3794/#creatine.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Five variants predicted to be possibly damaging (using in silico analysis tools including p.Pro8Thr, p.Tyr27His p.Met71Val, p.Val95Ile, and p.Thr146Arg) showed normal GAMT enzyme activity using site-directed mutagenesis, and were thus determined to be non-pathogenic [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.desroches.2015.2163">Desroches et al 2015</a>].</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK3794/table/creatine.T.selected_gamt_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="figcreatineTselectedgamtpathogenicvari" rid-ob="figobcreatineTselectedgamtpathogenicvari">Table 6</a>. About 60 different pathogenic variants located in various exons have been found in individuals with GAMT deficiency [<a class="bk_pop" href="#creatine.REF.carducci.2000.633">Carducci et al 2000</a>, <a class="bk_pop" href="#creatine.REF.item.2004.524">Item et al 2004</a>, <a class="bk_pop" href="#creatine.REF.cheillan.2006.775">Cheillan et al 2006</a>, <a class="bk_pop" href="#creatine.REF.lionfran_ois.2006.1713">Lion-Fran&#x000e7;ois et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</a>, <a class="bk_pop" href="#creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</a>, <a class="bk_pop" href="#creatine.REF.dhar.2009.38">Dhar et al 2009</a>, <a class="bk_pop" href="#creatine.REF.orourke.2009.404">O'Rourke et al 2009</a>, <a class="bk_pop" href="#creatine.REF.sempere.2009a.745">Sempere et al 2009a</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p><i>GAMT</i> pathogenic variants comprise <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, splice errors, insertions, deletions, and frameshifts. The majority of pathogenic variants (&#x0003e;60%) are missense [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</a>, <a class="bk_pop" href="#creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</a>].</p><p>The most frequent pathogenic variants were c.327G&#x0003e;A (24%; 23/94 alleles) and c.59G&#x0003e;C (21%; 20/94 alleles), detected in 47 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; 27 of the 47 affected individuals were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> [<a class="bk_pop" href="#creatine.REF.carducci.2000.633">Carducci et al 2000</a>, <a class="bk_pop" href="#creatine.REF.item.2004.524">Item et al 2004</a>, <a class="bk_pop" href="#creatine.REF.cheillan.2006.775">Cheillan et al 2006</a>, <a class="bk_pop" href="#creatine.REF.lionfran_ois.2006.1713">Lion-Fran&#x000e7;ois et al 2006</a>, <a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>, <a class="bk_pop" href="#creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</a>, <a class="bk_pop" href="#creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</a>, <a class="bk_pop" href="#creatine.REF.dhar.2009.38">Dhar et al 2009</a>, <a class="bk_pop" href="#creatine.REF.orourke.2009.404">O'Rourke et al 2009</a>, <a class="bk_pop" href="#creatine.REF.sempere.2009a.745">Sempere et al 2009a</a>].</p><div id="creatine.T.selected_gamt_pathogenic_vari" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Selected <i>GAMT</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.selected_gamt_pathogenic_vari/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.selected_gamt_pathogenic_vari_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.59G&#x0003e;C</td><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp20Ser</td><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000156.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000156<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000147.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000147<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.327G&#x0003e;A&#x000a0;<sup>1</sup></td><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td></tr><tr><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.299_311dup13</td><td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg105GlyfsTer26</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="creatine.TF.6.1"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.327G&#x0003e;A changes the last nucleotide of the splice donor site of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2. Although no amino acid change is predicted, experimental analysis demonstrated that this one base substitution affects RNA-processing and yields two abnormal transcripts, one from skipping of exon 2 and the other from use of a cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 2 [<a class="bk_pop" href="#creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</a>].</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> GAMT, a cytosolic protein, catalyzes the second step of creatine biosynthesis. This enzyme converts guanidinoacetate and S-adenosylmethionine to creatine and S-adenosylhomocysteine. In humans, GAMT is expressed with highest activity in the liver and the pancreas and with lower activity in kidney. It is a monomeric protein of 236 amino acids with a relative molecular mass of 26,000-31,000 [<a class="bk_pop" href="#creatine.REF.velichkova.2006.16">Velichkova &#x00026; Himo 2006</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The first <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual described had severe deficiency of GAMT enzyme activity in the liver [<a class="bk_pop" href="#creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</a>]. Following development of an assay for GAMT enzyme activity in skin fibroblasts or Epstein-Barr virus transformed lymphoblasts [<a class="bk_pop" href="#creatine.REF.ilas.2000.179">Ilas et al 2000</a>], undetectable GAMT enzyme activity was identified in 20 individuals with GAMT deficiency [<a class="bk_pop" href="#creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</a>].</p></div><div id="creatine.GATM"><h4><i>GATM</i></h4><p><b>Gene structure.</b> The normal <i>GATM</i> <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA is 16,858 bp in length and comprises nine exons [<a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK3794/#creatine.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Only seven <i>GATM</i> pathogenic variants causing AGAT deficiency have been reported (see <a class="figpopup" href="/books/NBK3794/table/creatine.T.selected_gatm_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="figcreatineTselectedgatmpathogenicvari" rid-ob="figobcreatineTselectedgatmpathogenicvari">Table 7</a>). Five pathogenic variants occurred in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state.</p><div id="creatine.T.selected_gatm_pathogenic_vari" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Selected <i>GATM</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.selected_gatm_pathogenic_vari/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.selected_gatm_pathogenic_vari_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.446G&#x0003e;A&#x000a0;<sup>2</sup><br />(9297G&#x0003e;A)</td><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp149Ter</td><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_001482.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001482<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_001473.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001473<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.484+1G&#x0003e;T<br />(IVS3+1G&#x0003e;T)&#x000a0;<sup>3</sup></td><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1111dupA&#x000a0;<sup>4</sup></td><td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met371AsnfsTer6</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="creatine.TF.7.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="creatine.TF.7.2"><p class="no_margin">The c.446G&#x0003e;A pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant predicts a severely truncated protein lacking the active-site cysteine residue 407 [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>].</p></div></dd><dt>3. </dt><dd><div id="creatine.TF.7.3"><p class="no_margin">Nucleotide change results in skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 at the RNA level (r.289_484del196) [<a class="bk_pop" href="#creatine.REF.johnston.2005">Johnston et al 2005</a>].</p></div></dd><dt>4. </dt><dd><div id="creatine.TF.7.4"><p class="no_margin"><a class="bk_pop" href="#creatine.REF.edvardson.2010.228">Edvardson et al [2010]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> AGAT catalyzes the first reaction in creatine biosynthesis and transfers amidino group from arginine to glycine to form ornithine and guanidinoacetate. Guanidinocetate is the precursor of creatine. Mainly found in kidney, AGAT is located in the cytosol and in the intermembrane space of mitochondria. AGAT is the rate-limiting enzyme of creatine biosynthesis. AGAT enzyme activity is inhibited by creatine via expression of the protein in <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> level. AGAT enzyme activity is inhibited by ornithine allosterically.</p><p>Human mitochondrial AGAT is synthesized as a precursor of 423 amino acids from which the N-terminal 37 residues are cleaved off when the protein is transported to the mitochondrial intermembrane space, yielding a mature protein of 386 amino acid residues. The cytosolic form of AGAT consists of 391 amino acids [<a class="bk_pop" href="#creatine.REF.humm.1997.3373">Humm et al 1997</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The effect of two reported pathogenic alleles (p.Trp149Ter and p.Ala97ValfsTer11) showed no detectable enzyme activity in the cultivated lymphoblasts [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>, <a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>, <a class="bk_pop" href="#creatine.REF.ndika.2012.48">Ndika et al 2012</a>]. Cell extracts from the <a class="def" href="/books/n/gene/glossary/def-item/obligate-carrier/">obligate carrier</a> parents of the first described Italian family showed intermediate residual enzyme activity, as would be expected for the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state [<a class="bk_pop" href="#creatine.REF.item.2001.1127">Item et al 2001</a>, <a class="bk_pop" href="#creatine.REF.battini.2002.326">Battini et al 2002</a>].</p></div><div id="creatine.SLC6A8"><h4><i>SLC6A8</i></h4><p><b>Gene structure.</b>
<i>SLC6A8</i> comprises 13 exons and spans 8.4 kb. The SLC6A8 <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is 3,580 bp (reference sequence <a href="/nuccore/NM_005629.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005629.3</a>) [<a class="bk_pop" href="#creatine.REF.salomons.2001.1497">Salomons et al 2001</a>]. <i>SLC6A8</i>, on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> Xq28, has a <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a> <i>SLC6A10</i> (on chromosome 16p11.2) that has a premature stop codon in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 [<a class="bk_pop" href="#creatine.REF.clark.2006.604">Clark et al 2006</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK3794/#creatine.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The <a href="http://www.lovd.nl/SLC6A8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD Database</a> lists 65 reported pathogenic variants from 85 families with SLC6A8 deficiency [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</a>]. The most common pathogenic variants were <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> (31%) and three-<a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> (<a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a>) deletions (24%) [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>]. Certain pathogenic variants have been detected in several unrelated families. For example, c.1006_1008delAAC (in 5 families) and c.1222_1224delTTC (in 7 families) both result in the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of a three-nucleotide <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> [<a class="bk_pop" href="#creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</a>]. The pathogenic nature of many missense variants has been established by overexpression in primary SLC6A8-deficient cells for 20 missense variants [<a class="bk_pop" href="#creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</a>, <a class="bk_pop" href="#creatine.REF.betsalel.2011.56">Betsalel et al 2011</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>].</p><p>Single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions up to whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions and even <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> have been reported [<a class="bk_pop" href="#creatine.REF.anselm.2006.214">Anselm et al 2006</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2015.141">van de Kamp et al 2015</a>, <a href="http://www.lovd.nl/SLC6A8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD Database</a>].</p><div id="creatine.T.selected_slc6a8_pathogenic_va" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Selected <i>SLC6A8</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3794/table/creatine.T.selected_slc6a8_pathogenic_va/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__creatine.T.selected_slc6a8_pathogenic_va_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.321_323delCTT<br />(319_321delCTT)</td><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe107del</td><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_005629.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005629<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_005620.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_005620<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1222_1224delTTC<br />(1221_1223delTTC)</td><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe408del</td></tr><tr><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1631C&#x0003e;T</td><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro544Leu</td></tr><tr><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1661C&#x0003e;T</td><td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro554Leu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="creatine.TF.8.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The SLC6A8 protein is a member of a solute <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> family of Na+ and Cl- dependent transporters responsible for the uptake of certain neurotransmitters (noradrenalin, serotonin, GABA, dopamine) and amino acids (glycine, proline, taurine) [<a class="bk_pop" href="#creatine.REF.nash.1994.165">Nash et al 1994</a>]. The SLC6A8 protein comprises 635 amino acids with a molecular weight of 70 kd.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> All pathogenic variants resulted in impaired creatine uptake in fibroblasts when cultured at physiologic levels of creatine [<a class="bk_pop" href="#creatine.REF.salomons.2003.309">Salomons et al 2003</a>, <a class="bk_pop" href="#creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</a>]. In the presence of a strong suspicion of CRTR deficiency in a male (e.g., elevated urine creatine-to-creatinine ratio or creatine deficiency in the brain <sup>1</sup>H-MRS) with no detected <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or with a novel variant of uncertain pathogenicity, creatine uptake studies in cultured fibroblasts are important in the assessment of CRTR deficiency. In males the creatine uptake is less than 10% of normal control fibroblasts (incubated with 25 &#x000b5;mol creatine) [<a class="bk_pop" href="#creatine.REF.salomons.2001.1497">Salomons et al 2001</a>, <a class="bk_pop" href="#creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</a>]. This testing may also be valuable in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female with a novel variant of uncertain pathogenicity, but due to skewed X-inactivation a normal creatine uptake does not rule out CRTR deficiency.</p></div></div></div><div id="creatine.References"><h2 id="_creatine_References_">References</h2><div id="creatine.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.akiyama.2014.65">Akiyama T, Osaka H, Shimbo H, Nakajiri T, Kobayashi K, Oka M, Endoh F, Yoshinaga H. A Japanese adult case of guanidinoacetate methyltransferase deficiency. <span><span class="ref-journal">JIMD Rep. </span>2014;<span class="ref-vol">12</span>:65–9.</span> [<a href="/pmc/articles/PMC3897789/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3897789</span></a>] [<a href="/pubmed/23846910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23846910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.almeida.2004.214">Almeida LS, Verhoeven NM, Roos B, Valongo C, Cardoso ML, Vilarinho L, Salomons GS, Jakobs C. Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">82</span>:214–9.</span> [<a href="/pubmed/15234334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15234334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.anselm.2006.214">Anselm IA, Alkuraya FS, Salomons GS, Jakobs C, Fulton AB, Mazumdar M, Rivkin M, Frye R, Poussaint TY, Marsden D. X-linked creatine transporter defect: a report on two unrelated boys with a severe clinical phenotype. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:214–9.</span> [<a href="/pmc/articles/PMC2393549/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2393549</span></a>] [<a href="/pubmed/16601897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16601897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.anselm.2008.1642">Anselm IA, Coulter DL, Darras BT. Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1642–4.</span> [<a href="/pubmed/18443316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18443316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.barisic.2002.157">Barisic N, Bernert G, Ipsiroglu O, Stromberger C, Muller T, Gruber S, Prayer D, Moser E, Bittner RE, Stockler-Ipsiroglu S. Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. <span><span class="ref-journal">Neuropediatrics. </span>2002;<span class="ref-vol">33</span>:157–61.</span> [<a href="/pubmed/12200746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12200746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.battini.2006.828">Battini R, Alessandr&#x000ec; MG, Leuzzi V, Moro F, Tosetti M, Bianchi MC, Cioni G. Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn: early treatment can prevent phenotypic expression of the disease. <span><span class="ref-journal">J Pediatr. </span>2006;<span class="ref-vol">148</span>:828–30.</span> [<a href="/pubmed/16769397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.battini.2002.326">Battini R, Leuzzi V, Carducci C, Tosetti M, Bianchi MC, Item CB, Stockler-Ipsiroglu S, Cioni G. Creatine depletion in a new case with AGAT deficiency: clinical and genetic study in a large pedigree. <span><span class="ref-journal">Mol Genet Metab. </span>2002;<span class="ref-vol">77</span>:326–31.</span> [<a href="/pubmed/12468279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12468279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.betsalel.2011.56">Betsalel OT, Rosenberg EH, Almeida LS, Kleefstra T, Schwartz CE, Valayannopoulos V, Abdul-Rahman O, Poplawski N, Vilarinho L, Wolf P, den Dunnen JT, Jakobs C, Salomons GS. Characterization of novel SLC6A8 variants with the use of splice-site analysis tools and implementation of a newly developed LOVD database. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:56–63.</span> [<a href="/pmc/articles/PMC3039501/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3039501</span></a>] [<a href="/pubmed/20717164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20717164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.betsalel.2012.596">Betsalel OT, Pop A, Rosenberg EH, Fernandez-Ojeda M. Creatine Transporter Research, Group, Jakobs C, Salomons GS. Detection of variants in SLC6A8 and functional analysis of unclassified missense variants. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:596–601.</span> [<a href="/pubmed/22281021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22281021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.betsalel.2008.183">Betsalel OT, van de Kamp JM, Mart&#x000ed;nez-Mu&#x000f1;oz C, Rosenberg EH, de Brouwer AP, Pouwels PJ, van der Knaap MS, Mancini GM, Jakobs C, Hamel BC, Salomons GS. Detection of low-level somatic and germline mosaicism by denaturing high-performance liquid chromatography in a EURO-MRX family with SLC6A8 deficiency. <span><span class="ref-journal">Neurogenetics. </span>2008;<span class="ref-vol">9</span>:183–90.</span> [<a href="/pubmed/18350323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18350323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.boenzi.2012.647">Boenzi S, Pastore A, Martinelli D, Goffredo BM, Boiani A, Rizzo C, Dionisi-Vici C. Creatine metabolism in urea cycle defects. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:647–53.</span> [<a href="/pubmed/22644604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22644604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.braissant.2008.230">Braissant O, Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span>:230–9.</span> [<a href="/pubmed/18392746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18392746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.caldeira_ara_jo.2005.122">Caldeira Ara&#x000fa;jo H, Smit W, Verhoeven NM, Salomons GS, Silva S, Vasconcelos R, Tom&#x000e1;s H, Tavares de Almeida I, Jakobs C, Duran M. Guanidinoacetate methyltransferase deficiency identified in adults and a child with mental retardation. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">133A</span>:122–7.</span> [<a href="/pubmed/15651030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15651030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.carducci.2000.633">Carducci C, Leuzzi V, Carducci C, Prudente S, Mercuri L, Antonozzi I. Two new severe mutations causing guanidinoacetate methyltransferase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2000;<span class="ref-vol">71</span>:633–8.</span> [<a href="/pubmed/11136556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11136556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.cecil.2001.401">Cecil KM, Salomons GS, Ball WS Jr, Wong B, Chuck G, Verhoeven NM, Jakobs C, DeGrauw TJ. Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:401–4.</span> [<a href="/pubmed/11261517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11261517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.cheillan.2006.775">Cheillan D, Salomons GS, Acquaviva C, Boisson C, Roth P, Cordier MP, Francois L, Jakobs C, Vianey-Saban C. Prenatal diagnosis of guanidinoacetate methyltransferase deficiency: increased guanidinoacetate concentrations in amniotic fluid. <span><span class="ref-journal">Clin Chem. </span>2006;<span class="ref-vol">52</span>:775–7.</span> [<a href="/pubmed/16595836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16595836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.cheillan.2012.96">Cheillan D, Joncquel-Chevalier Curt M, Briand G, Salomons GS, Mention-Mulliez K, Dobbelaere D, Cuisset JM, Lion-Fran&#x000e7;ois L, Portes VD, Chabli A, Valayannopoulos V, Benoist JF, Pinard JM, Simard G, Douay O, Deiva K, Afenjar A, H&#x000e9;ron D, Rivier F, Chabrol B, Prieur F, Cartault F, Pitelet G, Goldenberg A, Bekri S, Gerard M, Delorme R, Tardieu M, Porchet N, Vianey-Saban C, Vamecq J. Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:96.</span> [<a href="/pmc/articles/PMC3552865/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3552865</span></a>] [<a href="/pubmed/23234264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23234264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.clark.2006.604">Clark AJ, Rosenberg EH, Almeida LS, Wood TC, Jakobs C, Stevenson RE, Schwartz CE, Salomons GS. X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. <span><span class="ref-journal">Hum Genet. </span>2006;<span class="ref-vol">119</span>:604–10.</span> [<a href="/pubmed/16738945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16738945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.cognat.2004.1459">Cognat S, Cheillan D, Piraud M, Roos B, Jakobs C, Vianey-Saban C. Determination of guanidinoacetate and creatine in urine and plasma by liquid chromatography-tandem mass spectrometry. <span><span class="ref-journal">Clin Chem. </span>2004;<span class="ref-vol">50</span>:1459–61.</span> [<a href="/pubmed/15277360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15277360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.comeaux.2013.260">Comeaux MS, Wang J, Wang G, Kleppe S, Zhang VW, Schmitt ES, Craigen WJ, Renaud D, Sun Q, Wong LJ. Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">109</span>:260–8.</span> [<a href="/pubmed/23660394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23660394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.degrauw.2003.45">deGrauw TJ, Cecil KM, Byars AW, Salomons GS, Ball WS, Jakobs C. The clinical syndrome of creatine transporter deficiency. <span><span class="ref-journal">Mol Cell Biochem. </span>2003;<span class="ref-vol">244</span>:45–8.</span> [<a href="/pubmed/12701808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12701808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.desroches.2015.2163">Desroches CL, Patel J, Wang P, Minassian B, Marshall CR, Salomons GS, Mercimek-Mahmutoglu S. Carrier frequency of guanidinoacetate methyltransferase deficiency in the general population by functional characterization of missense variants in the GAMT gene. <span><span class="ref-journal">Mol Genet Genomics. </span>2015;<span class="ref-vol">290</span>:2163–71.</span> [<a href="/pubmed/26003046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26003046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.dhar.2009.38">Dhar SU, Scaglia F, Li FY, Smith L, Barshop BA, Eng CM, Haas RH, Hunter JV, Lotze T, Maranda B, Willis M, Abdenur JE, Chen E, O'Brien W, Wong LJ. Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2009;<span class="ref-vol">96</span>:38–43.</span> [<a href="/pubmed/19027335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19027335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.edvardson.2010.228">Edvardson S, Korman SH, Livne A, Shaag A, Saada A, Nalbandian R, Allouche-Arnon H, Gomori JM, Katz-Brull R. L-arginine:glycine amidinotransferase (AGAT) deficiency: clinical presentation and response to treatment in two patients with a novel mutation. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">101</span>:228–32.</span> [<a href="/pubmed/20682460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20682460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.elgharbawy.2013.215">El-Gharbawy AH, Goldstein JL, Millington DS, Vaisnins AE, Schlune A, Barshop BA, Schulze A, Koeberl DD, Young SP. Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">109</span>:215–7.</span> [<a href="/pubmed/23583224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23583224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.engelke.2009.538">Engelke UF, Tassini M, Hayek J, de Vries M, Bilos A, Vivi A, Valensin G, Buoni S, Zannolli R, Brussel W, Kremer B, Salomons GS, Veendrick-Meekes MJ, Kluijtmans LA, Morava E, Wevers RA. Guanidinoacetate methyltransferase (GAMT) deficiency diagnosed by proton NMR spectroscopy of body fluids. <span><span class="ref-journal">NMR Biomed. </span>2009;<span class="ref-vol">22</span>:538–44.</span> [<a href="/pubmed/19288536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19288536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.fons.2009.2168">Fons C, Sempere A, Sanmart&#x000ed; FX, Arias A, P&#x000f3;o P, Pineda M, Ribes A, Merinero B, Vilaseca MA, Salomons GS, Artuch R, Campistol J. Epilepsy spectrum in cerebral creatine transporter deficiency. <span><span class="ref-journal">Epilepsia. </span>2009;<span class="ref-vol">50</span>:2168–70.</span> [<a href="/pubmed/19706062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19706062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.hahn.2002.1349">Hahn KA, Salomons GS, Tackels-Horne D, Wood TC, Taylor HA, Schroer RJ, Lubs HA, Jakobs C, Olson RL, Holden KR, Stevenson RE, Schwartz CE. X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:1349–56.</span> [<a href="/pmc/articles/PMC447610/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC447610</span></a>] [<a href="/pubmed/11898126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11898126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.humm.1997.3373">Humm A, Fritsche E, Steinbacher S, Huber R. Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. <span><span class="ref-journal">EMBO J. </span>1997;<span class="ref-vol">16</span>:3373–85.</span> [<a href="/pmc/articles/PMC1169963/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1169963</span></a>] [<a href="/pubmed/9218780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9218780</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.ilas.2000.179">Ilas J, M&#x000fc;hl A, St&#x000f6;ckler-Ipsiroglu S. Guanidinoacetate methyltransferase (GAMT) deficiency: non-invasive enzymatic diagnosis of a newly recognized inborn error of metabolism. <span><span class="ref-journal">Clin Chim Acta. </span>2000;<span class="ref-vol">290</span>:179–88.</span> [<a href="/pubmed/10660808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10660808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.item.2004.524">Item CB, Mercimek-Mahmutoglu S, Battini R, Edlinger-Horvat C, Stromberger C, Bodamer O, M&#x000fc;hl A, Vilaseca MA, Korall H, St&#x000f6;ckler-Ipsiroglu S. Characterization of seven novel mutations in seven patients with GAMT deficiency. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:524.</span> [<a href="/pubmed/15108290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15108290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.item.2001.1127">Item CB, St&#x000f6;ckler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, Tosetti M, Fornai F, Cioni G. Arginine:Glycine amindinotransferase (AGAT) deficiency: The third inborn error of creatine metabolism in humans. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:1127–33.</span> [<a href="/pmc/articles/PMC1274356/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274356</span></a>] [<a href="/pubmed/11555793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11555793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.johnston.2005">Johnston K, Plawner L, Cooper L, Salomons GS, Verhoeven NM, Jakobs C, Barkovich AJ. The second family with AGAT deficiency (creatine biosynthesis defect): diagnosis, treatment and the first prenatal diagnosis. Abstract 205. Salt Lake City, UT: American Society of Human Genetics 55th Annual Meeting; 2005.</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.kleefstra.2005.379">Kleefstra T, Rosenberg EH, Salomons GS, Stroink H, van Bokhoven H, Hamel BC, de Vries BB. Progressive intestinal, neurological and psychiatric problems in two adult males with cerebral creatine deficiency caused by an SLC6A8 mutation. <span><span class="ref-journal">Clin Genet. </span>2005;<span class="ref-vol">68</span>:379–81.</span> [<a href="/pubmed/16143026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16143026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.lionfran_ois.2006.1713">Lion-Fran&#x000e7;ois L, Cheillan D, Pitelet G, Acquaviva-Bourdain C, Bussy G, Cotton F, Guibaud L, G&#x000e9;rard D, Rivier C, Vianey-Saban C, Jakobs C, Salomons GS, des Portes V. High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:1713–4.</span> [<a href="/pubmed/17101918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17101918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mancardi.2007.1211">Mancardi MM, Caruso U, Schiaffino MC, Baglietto MG, Rossi A, Battaglia FM, Salomons GS, Jakobs C, Zara F, Veneselli E, Gaggero R. Severe epilepsy in X-linked creatine transporter defect (CRTR-D). <span><span class="ref-journal">Epilepsia. </span>2007;<span class="ref-vol">48</span>:1211–3.</span> [<a href="/pubmed/17553121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17553121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mancini.2005.288">Mancini GM, Catsman-Berrevoets CE, de Coo IF, Aarsen FK, Kamphoven JH, Huijmans JG, Duran M, van der Knaap MS, Jakobs C, Salomons GS. Two novel mutations in SLC6A8 cause creatine transporter defect and distinctive X-linked mental retardation in two unrelated Dutch families. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">132A</span>:288–95.</span> [<a href="/pubmed/15690373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15690373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.martinelli.2012.761">Martinelli D, H&#x000e4;berle J, Rubio V, Giunta C, Hausser I, Carrozzo R, Gougeard N, Marco-Mar&#x000ed;n C, Goffredo BM, Meschini MC, Bevivino E, Boenzi S, Colafati GS, Brancati F, Baumgartner MR, Dionisi-Vici C. Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:761–6.</span> [<a href="/pubmed/22170564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22170564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu S, Connolly MB, Poskitt KJ, Horvath GA, Lowry N, Salomons GS, Casey B, Sinclair G, Davis C, Jakobs C, Stockler-Ipsiroglu S. Treatment of intractable epilepsy in a female with SLC6A8 deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2010a;<span class="ref-vol">101</span>:409–12.</span> [<a href="/pubmed/20846889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20846889</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2012a.155">Mercimek-Mahmutoglu S, Dunbar M, Friesen A, Garret S, Hartnett C, Huh L, Sinclair G, Stockler S, Wellington S, Pouwels PJ, Salomons GS, Jakobs C. Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2012a;<span class="ref-vol">105</span>:155–8.</span> [<a href="/pubmed/22019491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22019491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu S, Ndika J, Kanhai W, de Villemeur TB, Cheillan D, Christensen E, Dorison N, Hannig V, Hendriks Y, Hofstede FC, Lion-Francois L, Lund AM, Mundy H, Pitelet G, Raspall-Chaure M, Scott-Schwoerer JA, Szakszon K, Valayannopoulos V, Williams M, Salomons GS. Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene. <span><span class="ref-journal">Hum Mutat. </span>2014a;<span class="ref-vol">35</span>:462–9.</span> [<a href="/pubmed/24415674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24415674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2010b.s101">Mercimek-Mahmutoglu S, Roland E, Huh L, Steinraths M, Connolly M, Salomons GS, Sinclair G, Jakobs C, Stockler-Ipsiroglu S. Six new patients with creatine deficiency syndromes identified by selective screening in British Columbia. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010b;<span class="ref-vol">33</span>:S101.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu S, Salomons GS, Chan A. Case study for the evaluation of current treatment recommendations of guanidinoacetate methyltransferase deficiency: ineffectiveness of sodium benzoate. <span><span class="ref-journal">Pediatr Neurol. </span>2014b;<span class="ref-vol">51</span>:133–7.</span> [<a href="/pubmed/24766785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24766785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2012b.433">Mercimek-Mahmutoglu S, Sinclair G, van Dooren SJ, Kanhai W, Ashcraft P, Michel OJ, Nelson J, Betsalel OT, Sweetman L, Jakobs C, Salomons GS. Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease. <span><span class="ref-journal">Mol Genet Metab. </span>2012b;<span class="ref-vol">107</span>:433–7.</span> [<a href="/pubmed/23031365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23031365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R, Araujo HC, Duran M, Ensenauer R, Fernandez-Alvarez E, Garcia P, Grolik C, Item CB, Leuzzi V, Marquardt I, Muhl A, Saelke-Kellermann RA, Salomons GS, Schulze A, Surtees R, van der Knaap MS, Vasconcelos R, Verhoeven NM, Vilarinho L, Wilichowski E, Jakobs C. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:480–4.</span> [<a href="/pubmed/16855203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16855203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.m_rkrid.2015.760">M&#x000f8;rkrid L, Rowe AD, Elgstoen KB, Olesen JH, Ruijter G, Hall PL, Tortorelli S, Schulze A, Kyriakopoulou L, Wamelink MM, van de Kamp JM, Salomons GS, Rinaldo P. Continuous age- and sex-adjusted reference intervals of urinary markers for cerebral creatine deficiency syndromes: a novel approach to the definition of reference intervals. <span><span class="ref-journal">Clin Chem. </span>2015;<span class="ref-vol">61</span>:760–8.</span> [<a href="/pubmed/25759465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25759465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.n_ntosalonen.1999.303">N&#x000e4;nto-Salonen K, Komu M, Lundbom N, Hein&#x000e4;nen K, Alanen A, Sipil&#x000e4; I, Simell O. Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">53</span>:303–7.</span> [<a href="/pubmed/10430418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.nash.1994.165">Nash SR, Giros B, Kingsmore SF, Rochelle JM, Suter ST, Gregor P, Seldin MF, Caron MG. Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. <span><span class="ref-journal">Receptors Channels. </span>1994;<span class="ref-vol">2</span>:165–74.</span> [<a href="/pubmed/7953292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7953292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.nasrallah.2012.427">Nasrallah F, Kraoua I, Joncquel-Chevalier Curt M, Bout MA, Taieb SH, Feki M, Khouja N, Briand G, Kaabachi N. Guanidinoacetate methyltransferase (GAMT) deficiency in two Tunisian siblings: clinical and biochemical features. <span><span class="ref-journal">Clin Lab. </span>2012;<span class="ref-vol">58</span>:427–32.</span> [<a href="/pubmed/22783571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22783571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.ndika.2012.48">Ndika JD, Johnston K, Barkovich JA, Wirt MD, O'Neill P, Betsalel OT, Jakobs C, Salomons GS. Developmental progress and creatine restoration upon long-term creatine supplementation of a patient with arginine:glycine amidinotransferase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">106</span>:48–54.</span> [<a href="/pubmed/22386973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22386973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.nouioua.2013.670">Nouioua S, Cheillan D, Zaouidi S, Salomons GS, Amedjout N, Kessaci F, Boulahdour N, Hamadouche T, Tazir M. Creatine deficiency syndrome. A treatable myopathy due to arginine-glycine amidinotransferase (AGAT) deficiency. <span><span class="ref-journal">Neuromuscul Disord. </span>2013;<span class="ref-vol">23</span>:670–4.</span> [<a href="/pubmed/23770102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23770102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.orourke.2009.404">O'Rourke DJ, Ryan S, Salomons G, Jakobs C, Monavari A, King MD. Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language. <span><span class="ref-journal">Dev Med Child Neurol. </span>2009;<span class="ref-vol">51</span>:404–7.</span> [<a href="/pubmed/19388150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19388150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.pitt.2014.303">Pitt JJ, Tzanakos N, Nguyen T. Newborn screening for guanidinoacetate methyl transferase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:303–4.</span> [<a href="/pubmed/24477282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24477282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.puusepp.2010.s5">Puusepp H, Kall K, Salomons GS, Talvik I, M&#x000e4;nnamaa M, Rein R, Jakobs C, Ounap K. The screening of SLC6A8 deficiency among Estonian families with X-linked mental retardation. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span> Suppl 3:S5–11.</span> [<a href="/pubmed/24137762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24137762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.rosenberg.2007.890">Rosenberg EH, Mart&#x000ed;nez Mu&#x000f1;oz C, Betsalel OT, van Dooren SJ, Fernandez M, Jakobs C, deGrauw TJ, Kleefstra T, Schwartz CE, Salomons GS. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:890–6.</span> [<a href="/pubmed/17465020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17465020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.salomons.2001.1497">Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, Jakobs C. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:1497–500.</span> [<a href="/pmc/articles/PMC1226136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226136</span></a>] [<a href="/pubmed/11326334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11326334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.salomons.2003.309">Salomons GS, van Dooren SJ, Verhoeven NM, Marsden D, Schwartz C, Cecil KM, DeGrauw TJ, Jakobs C. X-linked creatine transporter defect: an overview. <span><span class="ref-journal">J Inherit Metab Dis. </span>2003;<span class="ref-vol">26</span>:309–18.</span> [<a href="/pubmed/12889669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12889669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.schulze.2003.248">Schulze A, Bachert P, Schlemmer H, Harting I, Polster T, Salomons GS, Verhoeven NM, Jakobs C, Fowler B, Hoffmann GF, Mayatepek E. Lack of creatine in muscle and brain in an adult with GAMT deficiency. <span><span class="ref-journal">Ann Neurol. </span>2003;<span class="ref-vol">53</span>:248–51.</span> [<a href="/pubmed/12557293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12557293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.schulze.2001.413">Schulze A, Ebinger F, Rating D, Mayatepek E. Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. <span><span class="ref-journal">Mol Genet Metab. </span>2001;<span class="ref-vol">74</span>:413–9.</span> [<a href="/pubmed/11749046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11749046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.schulze.2006.719">Schulze A, Hoffmann GF, Bachert P, Kirsch S, Salomons GS, Verhoeven NM, Mayatepek E. Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:719–21.</span> [<a href="/pubmed/16924036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16924036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.schulze.1998.606">Schulze A, Mayatepek E, Bachert P, Marescau B, De Deyn PP, Rating D. Therapeutic trial of arginine restriction in creatine deficiency syndrome. <span><span class="ref-journal">Eur J Pediatr. </span>1998;<span class="ref-vol">157</span>:606–7.</span> [<a href="/pubmed/9686828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9686828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.sempere.2009a.745">Sempere A, Fons C, Arias A, Rodr&#x000ed;guez-Pombo P, Merinero B, Alcaide P, Capdevila A, Ribes A, Duque R, Eir&#x000ed;s J, Poo P, Fern&#x000e1;ndez-Alvarez E, Campistol J, Artuch R. Cerebral creatine deficiency: first Spanish patients harbouring mutations in GAMT gene. <span><span class="ref-journal">Med Clin (Barc). </span>2009a;<span class="ref-vol">133</span>:745–9.</span> [<a href="/pubmed/19892372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19892372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.sempere.2009b.s91">Sempere A, Fons C, Arias A, Rodr&#x000ed;guez-Pombo P, Colomer R, Merinero B, Alcaide P, Capdevila A, Ribes A, Artuch R, Campistol J. Creatine transporter deficiency in two adult patients with static encephalopathy. <span><span class="ref-journal">J Inherit Metab Dis. </span>2009b;<span class="ref-vol">32</span> Suppl 1:S91–6.</span> [<a href="/pubmed/19319661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19319661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.st_ckler.1996.914">St&#x000f6;ckler S, Isbrandt D, Hanefeld F, Schmidt B, von Figura K. Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">58</span>:914–22.</span> [<a href="/pmc/articles/PMC1914613/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1914613</span></a>] [<a href="/pubmed/8651275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8651275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu S, Mercimek-Mahmutoglu S, Salomons G. Creatine deficiency syndromes. In: Saudubray JM, van den Berghe G, Walter JH, eds. <em>Inborn Metabolic Diseases. Diagnosis and Treatment.</em> 5 ed. Springer-Verlag; 2012:239-47.</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu S, van Karnebeek C, Longo N, Korenke GC, Mercimek-Mahmutoglu S, Marquart I, Barshop B, Grolik C, Schlune A, Angle B, Ara&#x000fa;jo HC, Coskun T, Diogo L, Geraghty M, Haliloglu G, Konstantopoulou V, Leuzzi V, Levtova A, Mackenzie J, Maranda B, Mhanni AA, Mitchell G, Morris A, Newlove T, Renaud D, Scaglia F, Valayannopoulos V, van Spronsen FJ, Verbruggen KT, Yuskiv N. Nyhan, Schulze A. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:16–25.</span> [<a href="/pubmed/24268530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24268530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.trotierfaurion.2015.185">Trotier-Faurion A, Passirani C, B&#x000e9;jaud J, D&#x000e9;zard S, Valayannopoulos V, Taran F, de Lonlay P, Benoit JP, Mabondzo A. Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. <span><span class="ref-journal">Nanomedicine (Lond). </span>2015;<span class="ref-vol">10</span>:185–91.</span> [<a href="/pubmed/24559037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24559037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.valayannopoulos.2012.151">Valayannopoulos V, Boddaert N, Chabli A, Barbier V, Desguerre I, Philippe A, Afenjar A, Mazzuca M, Cheillan D, Munnich A, de Keyzer Y, Jakobs C, Salomons GS, de Lonlay P. Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:151–7.</span> [<a href="/pubmed/21660517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21660517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2011.264">van de Kamp JM, Mancini GM, Pouwels PJ, Betsalel OT, van Dooren SJ, de Koning I, Steenweg ME, Jakobs C, van der Knaap MS, Salomons GS. Clinical features and X-inactivation in females heterozygous for creatine transporter defect. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">79</span>:264–72.</span> [<a href="/pubmed/20528887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20528887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2012.141">van de Kamp JM, Pouwels PJ, Aarsen FK, Ten Hoopen LW, Knol DL, de Klerk JB, de Coo IF, Huijmans JG, Jakobs C, van der Knaap MS, Salomons GS, Mancini GM. Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. <span><span class="ref-journal">J Inherit Metab Dis. </span>2012;<span class="ref-vol">35</span>:141–9.</span> [<a href="/pmc/articles/PMC3249187/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3249187</span></a>] [<a href="/pubmed/21556832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21556832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2013a.463">van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, Abdulhoul L, Grunewald S, Anselm I, Azzouz H, Bratkovic D, de Brouwer A, Hamel B, Kleefstra T, Yntema H, Campistol J, Vilaseca MA, Cheillan D, D'Hooghe M, Diogo L, Garcia P, Valongo C, Fonseca M, Frints S, Wilcken B, von der Haar S, Meijers-Heijboer HE, Hofstede F, Johnson D, Kant SG, Lion-Francois L, Pitelet G, Longo N, Maat-Kievit JA, Monteiro JP, Munnich A, Muntau AC, Nassogne MC, Osaka H, Ounap K, Pinard JM, Quijano-Roy S, Poggenburg I, Poplawski N, Abdul-Rahman O, Ribes A, Arias A, Yaplito-Lee J, Schulze A, Schwartz CE, Schwenger S, Soares G, Sznajer Y, Valayannopoulos V, Van Esch H, Waltz S, Wamelink MM, Pouwels PJ, Errami A, van der Knaap MS, Jakobs C, Mancini GM, Salomons GS. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. <span><span class="ref-journal">J Med Genet. </span>2013a;<span class="ref-vol">50</span>:463–72.</span> [<a href="/pubmed/23644449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23644449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2013b.155">van de Kamp JM, Jakobs C, Gibson KM, Salomons GS. New insights into creatine transporter deficiency: the importance of recycling creatine in the brain. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013b;<span class="ref-vol">36</span>:155–6.</span> [<a href="/pubmed/22968583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22968583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2014.715">van de Kamp JM, Mancini GM, Salomons GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:715–33.</span> [<a href="/pubmed/24789340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24789340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_de_kamp.2015.141">van de Kamp JM, Errami A, Howidi M, Anselm I, Winter S, Phalin-Roque J, Osaka H, van Dooren SJ, Mancini GM, Steinberg SJ, Salomons GS. Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">87</span>:141–7.</span> [<a href="/pubmed/24597975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24597975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.van_spronsen.2006.274">van Spronsen FJ, Reijngoud DJ, Verhoeven NM, Soorani-Lunsing RJ, Jakobs C, Sijens PE. High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">89</span>:274–6.</span> [<a href="/pubmed/16580861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16580861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.velichkova.2006.16">Velichkova P, Himo F. Theoretical study of the methyl transfer in guanidinoacetate methyltransferase. <span><span class="ref-journal">J Phys Chem B. </span>2006;<span class="ref-vol">110</span>:16–9.</span> [<a href="/pubmed/16471489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16471489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.verbruggen.2007.921">Verbruggen KT, Knijff WA, Soorani-Lunsing RJ, Sijens PE, Verhoeven NM, Salomons GS, Goorhuis-Brouwer SM, van Spronsen FJ. Global developmental delay in guanidinoacetate methyltransferase deficiency: differences in formal testing and clinical observation. <span><span class="ref-journal">Eur J Pediatr. </span>2007;<span class="ref-vol">166</span>:921–5.</span> [<a href="/pubmed/17186272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17186272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.verhoeven.2004.441">Verhoeven NM, Roos B, Struys EA, Salomons GS, van der Knaap MS, Jakobs C. Enzyme assay for diagnosis of guanidinoacetate methyltransferase deficiency. <span><span class="ref-journal">Clin Chem. </span>2004;<span class="ref-vol">50</span>:441–3.</span> [<a href="/pubmed/14752017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14752017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.verhoeven.2003.803">Verhoeven NM, Schor DS, Roos B, Battini R, Stockler-Ipsiroglu S, Salomons GS, Jakobs C. Diagnostic enzyme assay that uses stable-isotope-labeled substrates to detect L-arginine:glycine amidinotransferase deficiency. <span><span class="ref-journal">Clin Chem. </span>2003;<span class="ref-vol">49</span>:803–5.</span> [<a href="/pubmed/12709373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12709373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.verma.2010.186">Verma A. Arginine:glycine amidinotransferase deficiency: a treatable metabolic encephalomyopathy. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:186–8.</span> [<a href="/pubmed/20625172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20625172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.pasquali.2014.231">Pasquali M, Schwarz E, Jensen M, Yuzyuk T, DeBiase I, Randall H, Longo N. Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:231–6.</span> [<a href="/pubmed/24276113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24276113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.viau.2013.255">Viau KS, Ernst SL, Pasquali M, Botto LD, Hedlund G, Longo N. Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">110</span>:255–62.</span> [<a href="/pubmed/24071436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24071436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.vodopiutz.2007.773">Vodopiutz J, Item CB, H&#x000e4;usler M, Korall H, Bodamer OA. Severe speech delay as the presenting symptom of guanidinoacetate methyltransferase deficiency. <span><span class="ref-journal">J Child Neurol. </span>2007;<span class="ref-vol">22</span>:773–4.</span> [<a href="/pubmed/17641269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17641269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="creatine.REF.wyss.2000.1107">Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. <span><span class="ref-journal">Physiol Rev. </span>2000;<span class="ref-vol">80</span>:1107–213.</span> [<a href="/pubmed/10893433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10893433</span></a>]</div></li></ul></div></div><div id="creatine.Chapter_Notes"><h2 id="_creatine_Chapter_Notes_">Chapter Notes</h2><div id="creatine.Author_History"><h3>Author History</h3><p>Saadet Mercimek-Mahmutoglu, MD, PhD, FCCMG (2008-present)<br />Gaija S Salomons, PhD (2008-present)<br />Sylvia St&#x000f6;ckler-Ipsiroglu, MD, PhD, MBA, FRCPC; University of British Columbia (2008-2015)</p></div><div id="creatine.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>10 December 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 January 2009 (me) Review posted live</div></li><li class="half_rhythm"><div>24 July 2008 (smm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK3794</span><span class="label">PMID: <a href="/pubmed/20301745" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301745</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cranio-md/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cf/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK3794&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK3794/?report=reader">PubReader</a></li><li><a href="/books/NBK3794/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK3794" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK3794" style="display:none" title="Cite this Page"><div class="bk_tt">Mercimek-Mahmutoglu S, Salomons GS. Creatine Deficiency Syndromes. 2009 Jan 15 [Updated 2015 Dec 10]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK3794/pdf/Bookshelf_NBK3794.pdf">PDF version of this page</a> (627K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#creatine.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#creatine.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#creatine.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#creatine.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#creatine.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#creatine.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#creatine.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#creatine.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#creatine.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#creatine.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#creatine.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#creatine.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6535[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC6A8</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2628[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GATM</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2593[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GAMT</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK3794+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1484816" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1484816" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1484816" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1484816" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25192512" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders.</a><span class="source">[Semin Neurol. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stockler-Ipsiroglu S, van Karnebeek CD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Neurol. 2014 Jul; 34(3):350-6. Epub 2014 Sep 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26542286" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Creatine biosynthesis and transport in health and disease.</a><span class="source">[Biochimie. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Creatine biosynthesis and transport in health and disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Joncquel-Chevalier Curt M, Voicu PM, Fontaine M, Dessein AF, Porchet N, Mention-Mulliez K, Dobbelaere D, Soto-Ares G, Cheillan D, Vamecq J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Biochimie. 2015 Dec; 119:146-65. Epub 2015 Nov 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15625559" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Biochemical and clinical characteristics of creatine deficiency syndromes.</a><span class="source">[Acta Biochim Pol. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Biochemical and clinical characteristics of creatine deficiency syndromes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sykut-Cegielska J, Gradowska W, Mercimek-Mahmutoglu S, Stöckler-Ipsiroglu S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Acta Biochim Pol. 2004; 51(4):875-82. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12889668" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism.</a><span class="source">[J Inherit Metab Dis. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stromberger C, Bodamer OA, Stöckler-Ipsiroglu S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Inherit Metab Dis. 2003; 26(2-3):299-308. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12324495" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Guanidinoacetate and creatine plus creatinine assessment in physiologic fluids: an effective diagnostic tool for the biochemical diagnosis of arginine:glycine amidinotransferase and guanidinoacetate methyltransferase deficiencies.</a><span class="source">[Clin Chem. 2002]</span><div class="brieflinkpop offscreen_noflow">Guanidinoacetate and creatine plus creatinine assessment in physiologic fluids: an effective diagnostic tool for the biochemical diagnosis of arginine:glycine amidinotransferase and guanidinoacetate methyltransferase deficiencies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Carducci C, Birarelli M, Leuzzi V, Carducci C, Battini R, Cioni G, Antonozzi I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Chem. 2002 Oct; 48(10):1772-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301745" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301745" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042b80dde0891169d2a952">Creatine Deficiency Syndromes - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Creatine Deficiency Syndromes - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:39:44-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88AABEE0424CA10000000002ED0123&amp;ncbi_session=CE88AABEE042B7F1_0749SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK3794%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK3794&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK3794/&amp;ncbi_pagename=Creatine Deficiency Syndromes - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88AABEE042B7F1_0749SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>